UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported): January 8, 2018
Encompass Health Corporation
(Exact Name of Registrant as Specified in its Charter)
Delaware
(State or Other Jurisdiction of Incorporation)

		
001-10315	63-0860407	
(Commission File Number)	(I.R.S. Employer Identification No.)	
 	 	
3660 Grandview Parkway, Suite 200, Birmingham, Alabama 35243
(Address of Principal Executive Offices, Including Zip Code)
(205) 967-7116
(Registrant's Telephone Number, Including Area Code)
HealthSouth Corporation
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

	
		
¨	Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)	
 	 	
¨	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)	
 	 	
¨	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))	
 	 	
¨	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))	
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.     Emerging growth company   o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

ITEM 7.01. Regulation FD Disclosure .
Encompass Health Corporation (the “Company” or “Encompass Health”) will participate in the 36 th Annual J.P. Morgan Healthcare Conference in San Francisco, California on January 8-11, 2018. Encompass Health President and Chief Executive Officer, Mark Tarr, will make a presentation on Tuesday, January 9 th , at 2:30 p.m. ET/11:30 a.m. PT using the slides attached to this Current Report on Form 8-K as Exhibit 99.1 (the “Conference Slides”) and incorporated herein by reference. The presentation will address, among other things, the Company's strategy and financial performance and discuss industry trends and dynamics. The presentation will be webcast live and will be available at http://investor.healthsouth.com by clicking on an available link.
The Company also has assembled the Investor Reference Book attached to this Current Report on Form 8‑K as Exhibit 99.2 (the “Investor Reference Book”). The Investor Reference Book addresses, among other things, an overview of the Company and its industry, its business outlook, its financial and operational metrics and initiatives, and its investment thesis and strategy. The Investor Reference Book is available at http://investor.healthsouth.com by clicking on an available link.
While the Company has not closed its books for the year ended December 31, 2017, the Company anticipates discussing certain observations regarding fourth quarter 2017 operating performance at the 36 th Annual J.P. Morgan Healthcare Conference as noted below. The Company currently expects to report strong volume growth in both segments for the fourth quarter of 2017. Total inpatient rehabilitation segment discharge growth in the fourth quarter of 2017 of approximately 5.8% benefited from accelerated discharges prior to the December holidays and compares to 1.4% discharge growth in the fourth quarter of 2016 (same-store discharge growth was approximately 3.9% in the fourth quarter of 2017 compared to 0.1% in the fourth quarter of 2016). Total home health and hospice segment admission growth in the fourth quarter of 2017 approximated 13.6%. Additionally, the Company shares its preliminary estimate of adjusted free cash flow for the year ended December 31, 2017 in the Conference Slides and Investor Reference Book and its preliminary estimate of debt reduction for the year ended December 31, 2017 in the Investor Reference Book.
The Company reiterates as of the date hereof its net operating revenues, Adjusted EBITDA, and adjusted earnings per share guidance ranges for 2017, as previously reported in the Current Report on Form 8-K, dated October 26, 2017, and during the Company’s earnings conference call held on October 27, 2017, but currently expects to be in the upper half of these guidance ranges.
The Company is also providing the following preliminary guidance ranges for 2018:

•	Net operating revenues of $4,150 million to $4,250 million;	
• Adjusted EBITDA of $830 million to $850 million; and
• Adjusted earnings per share from continuing operations attributable to Encompass Health of $3.25 to $3.40.
In the Investor Reference Book, the Company provides its estimate of the impact of the new revenue recognition accounting standard effective in the first quarter of 2018 on the net operating revenues guidance range above.
In addition, the Company shares its 2018 guidance considerations, preliminary assumptions around adjusted free cash flow, and opportunities for deploying its free cash flow in the Conference Slides and Investor Reference Book. The Company also provides its business outlook for 2018 through 2020 related to its strategy, revenue assumptions, and certain expense assumptions in the Investor Reference Book.
The Company uses “same-store” comparisons to explain the changes in certain performance metrics and line items within its financial statements. Same-store comparisons are calculated based on hospitals and agencies open throughout both the full current and prior periods presented. These comparisons include the financial results of market consolidation transactions in existing markets, as it is difficult to determine, with precision, the incremental impact of these transactions on the Company's results of operations.
The information contained herein is being furnished pursuant to Item 7.01 of Form 8-K, “Regulation FD Disclosure.” This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. The furnishing of this information will not be deemed an admission as to the materiality of any information contained herein.

Note Regarding Presentation of Non-GAAP Financial Measures
The financial data contained in the Conference Slides and the Investor Reference Book includes non-GAAP financial measures, including the Company’s adjusted earnings per share, leverage ratio, Adjusted EBITDA, and adjusted free cash flow.
Excluding net operating revenues, the Company does not provide guidance on a GAAP basis because it is unable to predict, with reasonable certainty, the future impact of items that are deemed to be outside the control of the Company or otherwise non-indicative of its ongoing operating performance. Such items include government, class action, and related settlements; professional fees—accounting, tax, and legal; mark-to-market adjustments for stock appreciation rights; gains or losses related to hedging instruments; loss on early extinguishment of debt; adjustments to its income tax provision (such as valuation allowance adjustments and settlements of income tax claims); items related to corporate and facility restructurings; and certain other items the Company believes to be non-indicative of its ongoing operating performance. These items cannot be reasonably predicted, will depend on several factors, including industry and market conditions, and could be material to the Company's results computed in accordance with GAAP. However, the following reasonably estimable GAAP measures for 2017 and 2018 would be included in the reconciliation for Adjusted EBITDA:

					
 	 	2017
Guidance	 	2018
Preliminary Guidance	
Provision for doubtful accounts as a percentage of net operating revenues	 	~ 1.6%	 	1.6% to 1.9%	
Interest expense and amortization of debt discounts and fees	 	~ $155 million	 	$147 million to $157 million	
Amortization of debt-related items	 	~ $7 million	 	~ $7 million	
The Company is providing adjusted earnings per share from continuing operations attributable to Encompass Health (“adjusted earnings per share”). The Company believes the presentation of adjusted earnings per share provides useful additional information to investors because it provides better comparability of ongoing operating performance to prior periods given that it excludes the impact of government, class action, and related settlements; professional fees—accounting, tax, and legal; mark-to-market adjustments for stock appreciation rights; gains or losses related to hedging instruments; loss on early extinguishment of debt; adjustments to its income tax provision (such as valuation allowance adjustments and settlements of income tax claims); items related to corporate and facility restructurings; and certain other items the Company believes to be non-indicative of its ongoing operating performance. It is reasonable to expect that one or more of these excluded items will occur in future periods, but the amounts recognized can vary significantly from period to period and may not directly relate to the Company’s ongoing operating performance. Accordingly, they can complicate comparisons of the Company’s results of operations across periods and comparisons of the Company’s results to those of other healthcare companies. Adjusted earnings per share should not be considered as a measure of financial performance under generally accepted accounting principles in the United States (“GAAP”) as the items excluded from it are significant components in understanding and assessing financial performance. Because adjusted earnings per share is not a measurement determined in accordance with GAAP and is thus susceptible to varying calculations, it may not be comparable as presented to other similarly titled measures of other companies. The Company reconciles adjusted earnings per share to earnings per share in the Investor Reference Book attached hereto as Exhibit 99.2.
The leverage ratio referenced therein is defined as the ratio of consolidated total debt to Adjusted EBITDA for the trailing four quarters. The Company believes its leverage ratio and Adjusted EBITDA are measures of its ability to service its debt and its ability to make capital expenditures. Additionally, the leverage ratio is a standard measurement used by investors to gauge the creditworthiness of an institution. The Company’s credit agreement also includes a maximum leverage ratio financial covenant which allows the Company to deduct up to $100 million of cash on hand from consolidated total debt. The Company reconciles Adjusted EBITDA to net income and to net cash provided by operating activities and Adjusted EBITDA for the Company’s reportable segments to net income from continuing operations before income tax expense in the Investor Reference Book attached hereto as Exhibit 99.2.
The Company uses Adjusted EBITDA on a consolidated basis as a liquidity measure. The Company believes this financial measure on a consolidated basis is important in analyzing its liquidity because it is the key component of certain material covenants contained within the Company’s credit agreement, which is discussed in more detail in Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations, “Liquidity and Capital Resources,” and Note 9, Long-term Debt , to the consolidated financial statements included in its Annual Report on Form 10‑K for the year ended December 31, 2016 (the “2016 Form 10‑K”). These covenants are material terms of the credit agreement. Noncompliance with these financial covenants under the credit agreement—its interest coverage ratio and its leverage ratio—

could result in the Company’s lenders requiring the Company to immediately repay all amounts borrowed. If the Company anticipated a potential covenant violation, it would seek relief from its lenders, which would have some cost to the Company, and such relief might be on terms less favorable to those in the Company’s existing credit agreement. In addition, if the Company cannot satisfy these financial covenants, it would be prohibited under the credit agreement from engaging in certain activities, such as incurring additional indebtedness, paying common stock dividends, making certain payments, and acquiring and disposing of assets. Consequently, Adjusted EBITDA is critical to the Company’s assessment of its liquidity.
In general terms, the credit agreement definition of Adjusted EBITDA, therein referred to as “Adjusted Consolidated EBITDA,” allows the Company to add back to consolidated net income interest expense, income taxes, and depreciation and amortization and then add back to consolidated net income (1) all unusual or nonrecurring items reducing consolidated net income (of which only up to $10 million in a year may be cash expenditures), (2) any losses from discontinued operations and closed locations, (3) costs and expenses, including legal fees and expert witness fees, incurred with respect to litigation associated with stockholder derivative litigation, and (4) share-based compensation expense, and (5) cost and expenses in connection with the Encompass Health rebranding. The Company also subtracts from consolidated net income all unusual or nonrecurring items to the extent they increase consolidated net income.
T he calculation of Adjusted EBITDA under the credit agreement does not require us to deduct net income attributable to noncontrolling interests or gains on disposal of assets and development activities. It also does not allow us to add back professional fees unrelated to the stockholder derivative litigation, losses on disposal of assets, unusual or nonrecurring cash expenditures in excess of $10 million, and charges resulting from debt transactions and development activities. These items and amounts, in addition to the items falling within the credit agreement's "unusual or nonrecurring" classification, may occur in future periods, but can vary significantly from period to period and may not directly relate to our ongoing operating performance. Accordingly, these items may not be indicative of the Company’s ongoing operating performance, so the Adjusted EBITDA calculation presented here includes adjustments for them.
Adjusted EBITDA is not a measure of financial performance under GAAP, and the items excluded from Adjusted EBITDA are significant components in understanding and assessing financial performance. Therefore, Adjusted EBITDA should not be considered a substitute for net income or cash flows from operating, investing, or financing activities. Because Adjusted EBITDA is not a measurement determined in accordance with GAAP and is thus susceptible to varying calculations, Adjusted EBITDA, as presented, may not be comparable to other similarly titled measures of other companies. Revenues and expenses are measured in accordance with the policies and procedures described in Note 1, Summary of Significant Accounting Policies , to the consolidated financial statements accompanying the 2016 Form 10‑K.
The Company also uses adjusted free cash flow as an analytical indicator to assess its performance. Management believes the presentation of adjusted free cash flow provides investors an efficient means by which they can evaluate the Company’s capacity to reduce debt, pursue development activities, and return capital to its common stockholders. The calculation of adjusted free cash flow and a reconciliation of net cash provided by operating activities to adjusted free cash flow are included in the Conference Slides and the Investor Reference Book attached hereto as Exhibit 99.1 and Exhibit 99.2, respectively. This measure is not a defined measure of financial performance under GAAP and should not be considered as an alternative to net cash provided by operating activities. The Company’s definition of adjusted free cash flow is limited and does not represent residual cash flows available for discretionary spending. Because this measure is not determined in accordance with GAAP and is susceptible to varying calculations, it may not be comparable to other similarly titled measures presented by other companies. See the consolidated statements of cash flows included in the 2016 Form 10-K and the condensed consolidated statements of cash flows included in the Company's quarterly report on Form 10-Q for the quarterly period ended September 30, 2017 for the GAAP measures of cash flows from operating, investing, and financing activities.
Forward-Looking Statements
Statements contained in this document, the Conference Slides attached hereto as Exhibit 99.1, and the Investor Reference Book attached hereto as Exhibit 99.2, which are not historical facts, such as those relating to the financial performance, guidance and assumptions, anticipated acquisitions and other development activities, business strategy, legislative and regulatory developments and their related impacts on the Company, capital expenditures, cyber security, dividend strategies, repurchases of securities, effective tax rates, business model, rebranding plans, and the positioning of services for the system of healthcare delivery in the future are forward-looking statements. In addition, the Company, through its senior management, may from time to time make forward-looking public statements concerning the matters described herein. All such estimates, projections, and forward-looking information speak only as of the date hereof, and the Company undertakes no duty to publicly update or revise such forward-looking information, whether as a result of new information, future events, or otherwise. Such forward-looking statements are necessarily estimates based upon current information, involve a number of risks and uncertainties, and relate to, among other things, future events, the Company’s plan to repurchase its debt or equity

securities, the Company’s financial plans, its future financial performance, its projected business results or model, its ability to return value to shareholders, its projected leverage ratio, its acquisition opportunities, and the impact of legislation or regulation. Actual events or results may differ materially from those anticipated in these forward-looking statements as a result of a variety of factors. While it is impossible to identify all such factors, factors which could cause actual events or results to differ materially from those estimated by the Company include, but are not limited to, the Company’s ability to comply with extensive, complex, and ever-changing regulations in the healthcare industry; the timing and effect of the rebranding initiative; the price of the Company’s common stock as it affects the Company’s willingness and ability to repurchase shares and the financial and accounting effects of any repurchases; any adverse outcome of various lawsuits, claims, and legal or regulatory proceedings involving the Company, including its pending DOJ and HHS-OIG investigations and any matters related to yet undiscovered issues, if any, at acquired companies; any adverse effects on operating performance of the Company’s stock price resulting from the integration of those acquisitions; potential disruptions, breaches, or other incidents affecting the proper operation, availability, or security of the Company’s information systems, including issues arising from the Meltdown and Spectre vulnerabilities and unauthorized access to or theft of patient, business associate, or other sensitive information or inability to provide patient care because of system unavailability as well as unforeseen issues, if any, related to integration of systems of any acquired companies; the ability to successfully integrate acquired companies, including realization of anticipated tax benefits, revenues, and cost savings, minimizing the negative impact on margins arising from the changes in staffing and other operating practices, and avoidance of unforeseen exposure to liabilities; significant changes in the Company’s management team; the Company’s ability to successfully complete and integrate de novo developments, acquisitions, investments, and joint ventures consistent with its growth strategy; changes, delays in (including in connection with resolution of Medicare payment reviews or appeals), or suspension of reimbursement for the Company’s services by governmental or private payors; changes in the regulation of the healthcare industry at either or both of the federal and state levels, including as part of national healthcare reform and deficit reduction; competitive pressures in the healthcare industry and the Company’s response thereto; the Company’s ability to obtain and retain favorable arrangements with third-party payors; the Company's ability to control costs, particularly labor and employee benefit costs, including group medical expenses; adverse effects resulting from coverage determinations made by Medicare Administrative Contractors regarding its Medicare reimbursement claims and lengthening delays in the Company's ability to recover improperly denied or recouped claims through the administrative appeals process on a timely basis; the Company's ability to adapt to changes in the healthcare delivery system, including involvement in coordinated care initiatives or programs that may arise with its referral sources and related impacts on volume or pricing and any significant changes that may result from the change in the executive branch of the U.S. government; the Company’s ability to attract and retain nurses, therapists, and other healthcare professionals in a highly competitive environment with often severe staffing shortages and the impact on the Company’s labor expenses from potential union activity and staffing shortages; general conditions in the economy and capital markets, including any crisis resulting from uncertainty in the sovereign debt market; the increase in the costs of defending and insuring against alleged professional liability claims and the Company’s ability to predict the estimated costs related to such claims; and other factors which may be identified from time to time in the Company’s SEC filings and other public announcements, including the Company’s Form 10‑K for the year ended December 31, 2016 and Form 10-Q for the quarters ended March 31, 2017, June 30, 2017 and September 30, 2017.
ITEM 9.01. Financial Statements and Exhibits.
(d)    Exhibits
99.1      Conference Slides of Encompass Health Corporation used in connection with its January 9, 2018 presentation at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco.
99.2      Encompass Health Corporation Investor Reference Book.

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.
ENCOMPASS HEALTH CORPORATION

			
 	 	 	
By:	/s/   D OUGLAS  E. C OLTHARP	
 	Name:	Douglas E. Coltharp	
 	Title:	Executive Vice President and Chief Financial Officer	

Dated: January 8, 2018

2018 J.P. Morgan Healthcare Conference Mark Tarr, President and Chief Executive Officer January 9, 2018 

 

Encompass Health 2 The information contained in this presentation includes certain estimates, projections and other forward-looking information that reflect Encompass Health’s current outlook, views and plans with respect to future events, including legislative and regulatory developments, strategy, capital expenditures, acquisition and other development activities, cyber security, dividend strategies, repurchases of securities, effective tax rates, financial performance, financial assumptions, business model, balance sheet and cash flow plans, disintermediation, and shareholder value-enhancing transactions. These estimates, projections and other forward-looking information are based on assumptions the Company believes, as of the date hereof, are reasonable. Inevitably, there will be differences between such estimates and actual events or results, and those differences may be material. There can be no assurance any estimates, projections or forward-looking information will be realized. All such estimates, projections and forward-looking information speak only as of the date hereof. Encompass Health undertakes no duty to publicly update or revise the information contained herein. You are cautioned not to place undue reliance on the estimates, projections and other forward-looking information in this presentation as they are based on current expectations and general assumptions and are subject to various risks, uncertainties and other factors, including those set forth in the Form 10-K for the year ended December 31, 2016, Form 10-Q for the quarters ended March 31, 2017, June 30, 2017, and September 30, 2017, and in other documents Encompass Health previously filed with the SEC, many of which are beyond Encompass Health’s control, that may cause actual events or results to differ materially from the views, beliefs and estimates expressed herein. Note Regarding Presentation of Non-GAAP Financial Measures The following presentation includes certain “non-GAAP financial measures” as defined in Regulation G under the Securities Exchange Act of 1934, including Adjusted EBITDA, leverage ratios, adjusted earnings per share, and adjusted free cash flow. The Company’s Form 8-K, dated January 8, 2018, to which the following presentation is attached as Exhibit 99.1, provides further explanation and disclosure regarding Encompass Health’s use of non-GAAP financial measures and should be read in conjunction with this presentation. Schedules that reconcile the non-GAAP financial measures included in the following presentation to the most directly comparable financial measures calculated and presented in accordance with Generally Accepted Accounting Principles in the United States are included in that Form 8-K. Forward-Looking Statements 

 

Encompass Health 3 Company Overview 

 

4Encompass Health Company Overview - Inpatient Rehabilitation 

 

5Encompass Health Company Overview - Home Health and Hospice 

 

Encompass Health 6 Market Overlap ~60% of the Company’s IRFs have an Encompass Health home health location within a 30-mile radius. Inpatient Rehabilitation and Home Health 

 

Encompass Health 7 Investment Thesis Encompass Health is positioned to become the nation’s leading provider of integrated post-acute services. The healthcare industry is evolving toward integrated delivery models and value-based care. Superior Performance Change Agility Strategic Relationships Quality of Patient Outcomes Cost Effectiveness Growth 

 

Encompass Health 8 80 70 60 50 40 30 20 10 0 2014 2018 2022 2026 2030 Both Segments Benefit from a Demographic Tailwind: Growth in the Medicare Beneficiary Population Projected Population of Age 65+ Age 80+Age 70-79Age 65-69 Millions 41% (19.0M) 43% (22.8M) 45% (27.0M) 46% (31.1M) 46% (33.8M) CAGR (Population Growth by Age) Age 2014to 2018 2018 to 2022 2022 to 2026 70-74 5.1% 3.8% 2.6% 75-79 4.1% 5.1% 5.0% ~3% CAGR Baby Boomer wave reaches average age of an Encompass Health Medicare patient (~76). 

 

Encompass Health 9 Elements of Strategy Strategy The Company’s strategy is to expand its network of inpatient rehabilitation hospitals and home health and hospice agencies, further strengthen its relationships with healthcare systems, provider networks, and payors in order to connect patient care across the healthcare continuum, and to deliver superior outcomes. Clinical Expertise and High-Quality Outcomes Financial Resources Advanced Technology Sustained Growth Post-Acute Innovation 

 

Encompass Health 10 2017 Summary GROWTH CAPITAL STRUCTURE OPERATIONAL INITIATIVES 4 New Hospitals Expanded Existing Hospitals by 166 Beds Acquired or Opened 15 Home Health Agencies Piloted Use of Enhanced Predictive Analytics Finalized Installation of Clinical Information System (ACE-IT) Formed Post-Acute Innovation Center Reduced Leverage Increased Liquidity Continued Shareholder Distributions Completed Clinical Collaboration TEAMWORKS 

 

Encompass Health 11 2018 Priorities GROWTH CAPITAL STRUCTURE OPERATIONAL INITIATIVES Hospitals Home HealthAgencies Hospice Agencies Rebranding and Name Change Post-Acute Patient Navigation Tools Clinical Collaboration Predictive Data Analytics Alternative Payment Models Opportunistic Refinancings Continued Shareholder Distributions 

 

Encompass Health 12 Guidance Adjusted EBITDA Adjusted Earnings per Share from Continuing Operations Attributable to Encompass Health Net Operating Revenues 2017 Guidance The Company currently expects to be in the upper half of these ranges. 2018 Preliminary Guidance Net Operating Revenues Adjusted EBITDA $830 million to $850 million Adjusted Earnings per Share from Continuing Operations Attributable to Encompass Health $3.25 to $3.40 $3,900 million to $3,950 million $810 million to $820 million $2.67 to $2.73 $4,150 million to $4,250 million 

 

Encompass Health 13 2018 Guidance Considerations Inpatient Rehabilitation u Estimated 0.8% increase in Medicare pricing for Q1 through Q3; ~1.25% for Q4 u Salary increase of ~3.0%; benefits increase of ~8.0% to 10.0% u Bad debt expense of 1.6% to 1.9% of net operating revenues Home Health and Hospice u Estimated 1.0% net Medicare pricing reduction for CY 2018 u Salary increase of ~3.0%; benefits increase of ~8.0% to 10.0% u Inclusive of home health and hospice acquisitions in 2018 Consolidated u Includes approximately $11 million to $13 million of operating expenses (included in corporate general and administrative expenses) associated with the rebranding and name change u Diluted share count of ~99.3 million shares u Tax rate of ~28% (includes impact from Tax Cuts and Jobs Act) 

 

Encompass Health 14 Adjusted Free Cash Flow Assumptions Certain Cash Flow Items (millions) 2017 Estimates 2018 Assumptions • Cash interest expense (net of amortization of debt discounts and fees) ~$148 $140 to $150 • Cash payments for taxes, net of refunds ~$100 $125 to $150 • Working Capital and Other $0 to $25 $50 to $70 • Maintenance CAPEX $140 to $150 $130 to $150 • Adjusted Free Cash Flow $387 to $432 $310 to $405 

 

Encompass Health 15 Free Cash Flow Priorities 2018 Assumptions (In Millions) Growth in Core Business IRF bed expansions $30 to $40 New IRFs - De novos 80 to 110 - Acquisitions opportunistic - Replacement IRFs and other 40 to 50 New home health and hospice acquisitions 50 to 100 $200 to $300, excluding IRF acquisitions Debt Reduction Debt redemptions (borrowings), net opportunistic Shareholder Distributions Cash dividends on common stock ~$100 Common stock repurchases opportunistic 2018 Assumptions 

 

Encompass Health 16 Strong and Sustainable Business Fundamentals Real Estate Ownership Attractive Healthcare Sectors Growth Opportunities Cost-Effectiveness Financial Strength Industry Leading Positions 

 

Committed to Delivering High-Quality, Cost-Effective Care Across the Post-Acute Continuum 

 

HealthSouth is a leading provider of post-acute healthcare services, offering both facility-based and home-based post-acute services in 34 states and Puerto Rico through its network of inpatient rehabilitation hospitals, home health agencies, and hospice agencies. Investor Reference Book Post Q3 2017 Earnings Release Last Updated January 8, 2018 

 

Encompass Health 2 Forward-Looking Statements The information contained in this Investor Reference Book includes certain estimates, projections and other forward- looking information that reflect Encompass Health’s current outlook, views and plans with respect to future events, including legislative and regulatory developments, strategy, capital expenditures, acquisition and other development activities, cyber security, dividend strategies, repurchases of securities, effective tax rates, financial performance, financial assumptions, business model, balance sheet and cash flow plans, disintermediation, and shareholder value- enhancing transactions. These estimates, projections and other forward-looking information are based on assumptions the Company believes, as of the date hereof, are reasonable. Inevitably, there will be differences between such estimates and actual events or results, and those differences may be material. There can be no assurance any estimates, projections or forward-looking information will be realized. All such estimates, projections and forward-looking information speak only as of the date hereof. Encompass Health undertakes no duty to publicly update or revise the information contained herein. You are cautioned not to place undue reliance on the estimates, projections and other forward-looking information in this Investor Reference Book as they are based on current expectations and general assumptions and are subject to various risks, uncertainties and other factors, including those set forth in the Form 10-K for the year ended December 31, 2016, Form 10-Q for the quarters ended March 31, 2017, June 30, 2017, and September 30, 2017, and in other documents Encompass Health previously filed with the SEC, many of which are beyond Encompass Health’s control, that may cause actual events or results to differ materially from the views, beliefs and estimates expressed herein. Note Regarding Presentation of Non-GAAP Financial Measures The following Investor Reference Book includes certain “non-GAAP financial measures” as defined in Regulation G under the Securities Exchange Act of 1934, including Adjusted EBITDA, leverage ratios, adjusted earnings per share, and adjusted free cash flow. Schedules are attached that reconcile the non-GAAP financial measures included in the following Investor Reference Book to the most directly comparable financial measures calculated and presented in accordance with Generally Accepted Accounting Principles in the United States. The Company’s Form 8-K, dated January 8, 2018, to which the following Investor Reference Book is attached as Exhibit 99.2, provides further explanation and disclosure regarding Encompass Health’s use of non-GAAP financial measures and should be read in conjunction with this Investor Reference Book. 

 

Encompass Health 3 Company Overview . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4-16 Investment Thesis and Strategy . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17-24 Business Outlook, Including Guidance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25-40 Growth . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41-52 Alternative Payment Models . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53-58 Capital Structure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59-64 Information Technology. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 65-68 Operational Metrics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 69-74 Industry Structure . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 75-87 Segment Operating Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 88-93 Reconciliations to GAAP and Share Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 94-105 End Notes. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 106-109 Table of Contents 

 

Encompass Health 4 Company Overview Encompass Health is a leading provider of inpatient rehabilitation and home-based care committed to delivering high-quality, cost-effective, integrated care across the post-acute continuum. 

 

Encompass Health 5 Portfolio as of December 31, 2017 Inpatient Rehabilitation Hospitals (“IRFs”) Home Health Locations Hospice Locations 6 Future IRFs** 36 States and Puerto Rico ~38,100 Employees * Excluding markets that have home health licensure barriers ** Previously announced under development † Based on 2016 data Note: One of the 127 IRFs and two of the 200 home health locations are nonconsolidated. These locations are accounted for using the equity method of accounting. Encompass Health A Leading Provider of Inpatient Rehabilitation and Home-Based Care Market Overlap ~60% of the Company’s IRFs have an Encompass Health home health location within a 30-mile radius.* Inpatient Rehabilitation - 12/31/17 127 IRFs (42 are Joint Ventures) 31 States and Puerto Rico ~29,400 Employees 22% of Licensed Beds† 29% of Medicare Patients Served† Key Statistics - Trailing 4 Quarters (9/30/17) ~169,500 Inpatient Discharges ~$3.1 Billion in Revenue Home Health and Hospice - 12/31/17 200 Home Health Locations 37 Hospice Locations 28 States ~8,700 Employees Key Statistics - Trailing 4 Quarters (9/30/17) ~121,000 Home Health Admissions ~4,500 Hospice Admissions ~$760 Million in Revenue Largest Owner and Operator of IRFs 4th Largest Provider of Medicare-Certified Skilled Home Health Services 

 

Encompass Health 6 Major Services • Rehabilitation Physicians: manage and treat medical conditions and oversee rehabilitation program • Rehabilitation Nurses: provide personal care and oversee treatment plan for patients • Physical Therapists: address physical function, mobility, strength, balance, and safety • Occupational Therapists: promote independence through activities of daily living (“ADLs”) • Speech-Language Therapists: address speech/voice functions, swallowing, memory/cognition, and language/communication • Case Managers: coordinate care plan with physician, Care Transition Coordinators, caregivers and family • Post-Discharge Services: outpatient therapy and home health Inpatient Rehabilitation Hospitals Refer to pages 106-109 for end notes. 105 of the Company’s IRFs hold one or more disease-specific certifications from The Joint Commission’s Disease-Specific Care Certification Program.(1) Company Overview Inpatient Rehabilitation 

 

Encompass Health 7 Major Services • Skilled Nurses: comprehensively assess, teach, train, and manage care related to injury or illness • Home Health Aides: provide personal care and assistance with ADLs • Physical Therapists: address physical function, mobility, strength, balance, and safety • Occupational Therapists: promote independence through training on self-management of ADLs • Speech-Language Therapists: address speech/voice functions, swallowing, memory/cognition, and language/communication • Medical Social Workers: provide assessment of social and emotional factors; assist with obtaining community resources Home Health Agencies The Company offers evidence-based specialty programs related to: Post-Operative Care, Fall Prevention, Chronic Disease Management, and Transitional Care. Hospice: provides services to terminally ill patients and their families to address patients’ physical needs, including pain control and symptom management, and also provides emotional and spiritual support. Company Overview Home Health and Hospice 

 

Encompass Health 8 IRF Patient Mix Referral Sources: • Physicians and acute care hospital case managers are key decision makers. • All IRF patients must meet reasonable and necessary criteria and must be admitted by a physician. • All IRF patients must be medically stable and have potential to tolerate three hours of therapy per day (minimum). • IRF patients receive 24-hour, 7 days a week nursing care. • Average length of stay = 12.7 days Admission to an IRF: Average Age of the Company’s IRF Patients: All Patients = 71 Medicare FFS = 76 Home Health Patient Mix Acute Care Hospitals – 92% Physician Offices / Community – 7% Skilled Nursing Facilities – 1% Referral Sources: • For Medicare, a patient must be confined to the home and need skilled services. • The patient must be under the care of a physician and receive services under a home health plan of care established and periodically reviewed by a physician. • Medicare also requires a face-to-face encounter related to the primary reason the patient requires home health services with a physician or an allowed non-physician practitioner. Admission to home health: 100 90 80 70 60 50 40 30 20 10 Pe rc en ta ge 24.0% 36.7% 31.9% 85.1% Age 85+ Lives alone Has 2 or more ADL limitations Has 3 or more chronic conditions Demographics of all Medicare Home Health Users**: * Rehabilitation Impairment Categories (RICs) represent how the Company admitted the patient; BPCI/CJR (pages 55-57) uses Diagnostic-Related Groups (DRGs) which represent how the acute care hospital discharged the patient. ** Source: Avalere Health and Alliance for Home Health Quality and Innovation Home Health Chart Book 2017 Rehabilitation Impairment Category* YTD-17 FY-16 RIC 01 Stroke 18.0% 17.6% RIC 02/03 Brain dysfunction 10.0% 9.4% RIC 04/05 Spinal cord dysfunction 4.0% 3.9% RIC 06 Neurological conditions 21.8% 20.4% RIC 07 Fracture of lower extremity 7.9% 8.1% RIC 08 Replacement of lower extremity joint 4.1% 5.1% RIC 09 Other orthopedic 9.2% 9.9% RIC 10/11 Amputation 2.6% 2.6% RIC 14 Cardiac 4.3% 4.7% RIC 17/18 Major multiple trauma 5.2% 5.2% RIC 20 Other disabling impairments 9.8% 10.0% — All other RICs 3.1% 3.1% Acute Care Hospitals – 36% Physician Offices / Community – 37% IRFs / LTCHs / SNFs – 27% Average Age of the Company’s Home Health Patients: All Patients = 76 Medicare FFS = 77 

 

Encompass Health 9 2015 2016 YTD 2017 10.6% 10.4% 10.4% 10.6% 10.7% 10.7% 2015 2016 YTD 2017 13.9% 13.1% 12.8% 10.7% 10.1% 9.3% 2015 2016 YTD 2017 75.2% 75.7% 75.9% 78.0% 78.7% 79.4% Home Health QualityIRF Quality Discharge to Community Discharge to Skilled Nursing Discharge to Acute Hospital Refer to pages 106-109 for end notes. 3.3 3.7 Quality of Care Star Ratings(3) 97% of our home health agencies are 3 Stars or higher; 49% are 4 Stars or higher 3.4 3.5 Patient Satisfaction Star Ratings(3) 99% of our home health agencies are 3 Stars or higher; 48% are 4 Stars or higher Encompass Health 16.9% 16.4% 30-Day Readmission Rate Percent of patients readmitted to an acute care hospital. Lower is better. 50 bps bette r UDSMR(2) Encompass Health Leading Positions in Quality of Care National Average Percent of cases discharged to the community, including home or home with home health. Higher is better. Percent of patients discharged to a skilled nursing facility. Lower is better. Percent of patients discharged to an acute care hospital. Lower is better. 

 

Encompass Health 10 Leading Position in Cost Effectiveness Inpatient Rehabilitation Medicare pays Encompass Health less per discharge, on average, and Encompass Health treats a higher acuity patient. # Avg. Beds per IRF Avg. Medicare Discharges per IRF(5) Case Mix Index(6) Avg. Est. Total Cost per Discharge for FY 2018 Avg. Est. Total Payment per Discharge for FY 2018 Encompass Health(4) = 123 67 955 1.26 $12,903 $19,776 Free-Standing = (Non-Encompass Health) 153 57 577 1.26 $17,363 $20,749 Hospital Units = 864 24 229 1.20 $20,798 $21,153 Total(7) 1,140 33 354 1.23 $17,753 $20,665 The average estimated total payment per discharge, as stated, does not reflect a 2% reduction for sequestration.(8) Refer to pages 106-109 for end notes. The Company differentiates itself by: Ÿ “Best Practices” clinical protocols Ÿ Supply chain efficiencies Ÿ Sophisticated management information systems Ÿ Economies of scale 

 

Encompass Health 11 2016 Episodes Average Revenue per Episode Average Visits per Episode Average Revenue per Visit Cost per Visit Encompass Health 185,737 $3,031 18.8 $154 $74 Public Peer Average 270,223 $2,825 17.5* $149 $86* Comparison to Peer Average 7.3% 7.4% 3.4% (14.0)% Public peer average represents 2016 data from publicly traded home health providers. * One publicly traded company (Kindred) does not report visit counts. Average revenue per episode is 7.3% higher than the peer average due to higher acuity patient mix. Cost per visit is 14.0% lower due to market density and operational efficiency: Ÿ Caregiver optimization Ÿ Optimization of HCHB Ÿ Employee culture of excellence Ÿ ~75% of visits conducted by full-time staff Ÿ Daily monitoring of productivity Leading Position in Cost Effectiveness Home Health 

 

Encompass Health 12 Hot Springs, AR (27 beds) 25.0 20.0 15.0 10.0 5.0 0.0 Q4 2014 Q1 2015 Q2 2015 Q3 2015 Q4 2015 Q1 2016 Q2 2016 Q3 2016 Q4 2016 Q1 2017 Q2 2017 Q3 2017Q4 2014 Q1 2015 Q2 2015 Q3 2015 Q4 2015 Q1 2016 Q2 2016 Q3 2016 Q4 2016 Q1 2017 Q2 2017 Q3 2017 Fairlawn(9) 1.9% 2.0% 1.1% New Store 0.6% 1.8% 4.4% 5.7% 15.6% 14.2% 11.7% 10.7% 1.3% 1.2% 1.9% 2.4% Same Store* 2.2% 2.9% 2.8% 3.9% 3.0% 2.8% 1.9% 1.9% 0.1% 1.6% 1.6% 1.4% Total by Qtr. 4.7% 6.7% 8.3% 9.6% 18.6% 17.0% 13.6% 12.6% 1.4% 2.8% 3.5% 3.8% Total by Year 3.5% 10.9% 10.8% Same-Store Year* 1.3% 3.2% 1.7% Same-Store Year UDS** (0.2)% 1.3% (0.6)% Altamonte Springs, FL (50 beds) Johnson City, TN (26 beds) Newnan, GA (50 beds) Middletown, DE (34 beds) Reliant (857 beds) Franklin, TN (40 beds) Lexington, KY (158 beds) Savannah, GA (50 beds) Bryan, TX (49 beds) Broken Arrow, OK (22 beds) Modesto, CA (50 beds) Gulfport, MS (33 beds) Westerville, OH (60 beds) Jackson, TN (48 beds) * Includes consolidated inpatient rehabilitation hospitals classified as same store during each period ** Data provider by UDSMR Refer to pages 106-109 for end notes. New-Store/Same-Store Growth Inpatient Rehabilitation 

 

Encompass Health 13 70.0 60.0 50.0 40.0 30.0 20.0 10.0 0.0 Q1 2016 Q2 2016 Q3 2016 Q4 2016 Q1 2017 Q2 2017 Q3 2017Admissions Q1 2016 Q2 2016 Q3 2016 Q4 2016 Q1 2017 Q2 2017 Q3 2017 New Store 43.5% 41.6% 35.4% 8.1% 5.7% 6.4% 6.7% Same Store* 12.6% 11.1% 15.3% 14.0% 13.9% 13.3% 8.8% Total by Quarter 56.1% 52.7% 50.7% 22.1% 19.6% 19.7% 15.5% Total by Year 43.6% Same-Store Year* 13.7% Acquired CareSouth (44 home health agencies in 7 states) in November 2015 * Includes consolidated home health agencies classified as same store during each period New-Store/Same-Store Growth Home Health u In 2016, the Company acquired or opened 10 home health locations. u In 2017, the Company acquired or opened 15 home health locations. 

 

Encompass Health 14 Medicaid Medicare Advantage Managed Care Medicare Other Per Diem/Visit or CMG/Episodes - Negotiated rate - Some are “tiered” for acuity/severity Per Diem/Visit or CMG/Episodes - Negotiated rate - Some are “tiered” for acuity/severity Prospective Payment System (“PPS”) - IRF: Paid per discharge by Case Mix Group (“CMG”) - Home Health: Paid per 60-day episode of care by Home Health Resource Group (“HHRG”) • An episode is paid in two installments: 1) Request for Anticipated Payment (“RAP”) 2) Final bill after episode is complete Varies by state Payors (Q3 2017) Payor Source Payment Methodology% of Revenues 85.2%73.3% 9.6% 8.1% 3.9% 10.7% 3.4% 1.1%4.5% 0.2% Inpatient Rehab Segment Home Health & Hospice Segment Variety of methodologies 

 

Encompass Health 15 Independent Research Concludes IRFs are a Better Rehabilitation Option for Stroke Patients than SNFs “If the hospital suggests sending your loved one to a skilled nursing facility after a stroke, advocate for the patient to go to an inpatient rehabilitation facility instead…”* “Whenever possible, the American Stroke Association strongly recommends that stroke patients be treated at an inpatient rehabilitation facility rather than a skilled nursing facility. While in an inpatient rehabilitation facility, a patient participates in at least three hours of rehabilitation a day from physical therapists, occupational therapists, and speech therapists. Nurses are continuously available and doctors typically visit daily.”* * ** AHA/ASA press release, “Inpatient rehab recommended over nursing homes for stroke rehab,” issued May 4, 2016 (newsroom.heart.org) “Guidelines for Adult Stroke Rehabilitation and Recovery,” issued May 2016 (stroke.ahajournals.org) “The studies that have compared outcomes in hospitalized stroke patients first discharged to an IRF, a SNF, or a nursing home have generally shown that IRF patients have higher rates of return to community living and greater functional recovery, whereas patients discharged to a SNF or a nursing home have higher rehospitalization rates and substantially poorer survival.”** 103 of the Company’s IRFs hold The Joint Commission’s Disease-Specific Care Certification in Stroke Rehabilitation. 

 

Encompass Health 16 • Largest provider of inpatient rehabilitation services • 4th largest provider of Medicare-certified skilled home health services • Consistent delivery of high-quality, cost-effective, integrated facility- based and home-based care • Enhanced utilization of technology (e.g., clinical, data management, and technology-enabled business processes) Strong and Sustainable Business Fundamentals • Effective labor management • Efficient supply chain • Economies related to scale and market density • Strong balance sheet and liquidity, no significant near-term maturities (credit agreement matures in 2022; bonds mature in 2023 and beyond) • Substantial free cash flow generation • Attractive organic growth opportunities in both segments • Flexible inpatient rehabilitation de novo and acquisition strategy • Home health and hospice platform with track record of growth through acquisitions • Portfolio of 127* IRFs as of December 31, 2017 P 88 owned and 39 leased • Favorable demographic trends driving increased demand • Nondiscretionary nature of many conditions treated • Highly fragmented post-acute sectors present acquisition and joint venture opportunities * Includes one nonconsolidated entity. Real Estate Ownership Attractive Healthcare Sectors Growth Opportunities Cost-Effectiveness Financial Strength Industry Leading Positions 

 

Encompass Health 17 Investment Thesis and Strategy Encompass Health’s ability to adapt to changes, build strategic relationships, and consistently provide high-quality, cost-effective care positions the Company for success in the evolving healthcare industry. 

 

Encompass Health 18 Investment Thesis Encompass Health is positioned to become the nation's leading provider of integrated post-acute services. The healthcare industry is evolving toward integrated delivery models and value-based care. Providers must be able to adapt to changes, build strategic relationships across the healthcare continuum, and consistently provide high-quality, cost-effective care to be successful. Change Agility Demonstrated ability to adapt across economic cycles and in the face of numerousand significant regulatory and legislative changes Strategic Relationships Joint ventures with acute-care partners comprise one-third of IRF portfolio. Formed Post-Acute Innovation Center in collaboration with Cerner Corporation to develop enhanced tools to manage patients across the continuum of care Partnered with the American Heart Association/American Stroke Association to jointly work to elevate national and local awareness that stroke is treatable and beatable through rehabilitation and community support. Quality of Patient Outcomes Outcomes in both operating segments exceed national industry standards. Cost Effectiveness Treatment of more medically-complex patients at lower average costs than other post-acute providers through superior clinical protocols, economies of scale, and technology-enabled business processes Growth Both of the Company's segments benefit from favorable demographic trends and thenondiscretionary nature of many conditions treated. 

 

Encompass Health 19 Elements of Strategy Strategy The Company’s strategy is to expand its network of inpatient rehabilitation hospitals and home health and hospice agencies, further strengthen its relationships with healthcare systems, provider networks, and payors in order to connect patient care across the healthcare continuum, and to deliver superior outcomes. Clinical Expertise and High-Quality Outcomes Financial Resources Advanced Technology Sustained Growth Post-Acute Innovation 

 

Encompass Health 20 Elements of Strategy Clinical Expertise and High-Quality Outcomes Institutional programs and advanced treatment protocols connect care and allow seamless transition of patients across the healthcare continuum Leverage technology to strengthen clinical data analytics Integration of care transition coordinators 105 Encompass Health inpatient rehabilitation hospitals hold one or more disease- specific certifications, including 103 with stroke-specific certifications Outcomes in both operating segments exceed national industry standards (see page 9) Financial Resources Strong, well-capitalized balance sheet Free cash flow funds growth and shareholder distributions Advanced Technology Proprietary rehabilitation-specific clinical information system (known as "ACE-IT") Proprietary management reporting system (known as "Beacon") Optimization of Homecare Homebase Sustained Growth Highly fragmented sectors present acquisition and joint venture growth opportunities Technology-facilitated and data-driven sales processes Barriers to entry include capital investments, clinical expertise, regulatory compliance, and Certificate of Need (“CON”) requirements Post-Acute Innovation Predictive analytics used to enhance patient outcomes (e.g., ReACT; Sepsis Alert) Ongoing innovation with initiatives such as the Post-Acute Innovation Center Active participant in various alternative payment models 

 

Encompass Health 21 Home-Based Post-Acute Services • More care in the home (lowest cost setting) • Ability to care for high-acuity patients with multiple chronic conditions Future Post-Acute Providers Inpatient Rehabilitation Hospitals • Full range: low acuity à high acuity • 24/7 nursing coverage • Eliminates payment silos • Integrated Delivery Payment Models • Value-Based Payments • Site Neutrality Current Post-Acute Providers Facility-Based Post Acute Services Skilled Nursing Facilities Home Health Long-Term Acute Care Hospitals • Medicare payments/regulations are site specific (e.g., 60% Rule, 3-Hour Rule, “preponderance” of one-to-one therapy). ▪ The Company believes the healthcare industry is moving toward integrated delivery payment models, value-based purchasing, and site neutrality. ▪ To succeed, providers must be able to adapt to changes in the regulatory and operating environments, build strategic relationships across the healthcare continuum, and consistently provide high-quality care at a cost-effective price. The Healthcare Landscape is Changing. • Medicare payments/regulations will be outcome focused. • Many existing regulations will become unnecessary. 

 

Encompass Health 22 Always Available Sometimes Available Seldom Available Therapy Gym & Training Systems for All PAC Patients Staff Trained for All Acuity Therapy Gym & Training Systems for All PAC Patients Staff Trained for All Acuity Therapy Gym & Training Systems for All PAC Patients Staff Trained for All Acuity LTACs IRFs SNFs Home Health The Company is Well-Positioned for the Progression Towards Site Neutrality as It Will be Able to Treat All Types of Post-Acute Patients by Leveraging Its Operational Expertise Across Its Network of Facility-Based and Home-Based Assets. Higher acuity patients will transition from post-acute inpatient hospitals to home health. Lower acuity patients will go directly to home health.Post-Acute Inpatient Spectrum Higher Acuity Lower Acuity Progression to Site Neutrality Post-Acute Inpatient Hospitals Presen t Futur e The Company’s IRFs have the physical construct, clinical staffing, and operating expertise to “pivot from the center” to address the full spectrum of inpatient post-acute needs in a site neutral environment. 

 

Encompass Health 23 The Company Continues to Make Progress on Improving the Patient Experience Through Integrated Care Delivery Inpatient Rehabilitation–Home Health Clinical Collaboration (All Payors) Overlap Markets* Q4 2016 Q4 2017 10,074 10,660 3,963 4,939 28.2% Collaboration Rate 31.7% Collaboration Rateu As of December 31, 2017, ~60% of Encompass Health’s inpatient rehabilitation hospitals were located within overlap markets.* u The clinical collaboration rate with Encompass Health’s inpatient rehabilitation hospitals increased by 350 basis points in Q4 2017 compared to Q4 2016. u The Company’s clinical collaboration rate goal for overlap markets is 35% to 40% within the next two years. u TeamWorks clinical collaboration is a process to identify and standardize best practices for integrated patient care. Ÿ Initiative launched in February 2017 Ÿ Began piloting redesigned clinical collaboration process in July 2017 Ÿ Implementation completed in December 2017 Encompass Health IRF Discharges to: Encompass Health Home Health Non-Encompass Health Home Health * Overlap markets are defined as a Company IRF that has an Encompass Health home health location within a 30-mile radius, excluding markets that have home health licensure barriers. Home health locations in overlap markets are open for 12 months before inclusion in the clinical collaboration rate. 

 

Encompass Health 24 Solution: Utilize extensive proprietary database of IRF patients to engage in predictive modeling to identify patients at risk for acute care transfer and implement intervention strategies as part of the plan of care. Solution: Standardize and improve infection control practices across the company in order to reduce the risk of infection to patients and apply evidenced- based decision making in the Company’s IRFs. Solution: Develop clinical protocols and coordinated discharge planning between IRFs and home health agencies; implement TeamWorks initiative to standardize best practices across all overlap markets; and integrate Care Transition Coordinators to implement patient-centered transition plans that promote quality, safety and patient choice. Problem: Acute care transfers can negatively influence patient outcomes and result in unnecessary healthcare expenditures and penalties. Problem: Infections are a threat to patient safety and add to growing healthcare costs. Problem: Poor coordination of the discharge process between healthcare providers can result in challenges with the transition of care, unnecessary duplication of services, and avoidable medical errors. Clinical Initiatives to Further Improve Quality Reduce Acute Care Transfers (tracked in the IRF QRP*) Infection Control Clinical Collaboration * IRF Quality Reporting Program 

 

Encompass Health 25 Business Outlook, Including Guidance (as of January 8, 2018) 

 

Encompass Health 26 2017 Summary GROWTH CAPITAL STRUCTURE OPERATIONAL INITIATIVES u Opened or acquired 4 new IRFs (including 3 joint ventures) Ÿ 6 IRF projects underway u Expanded existing IRFs by 166 beds u Acquired or opened 15 home health agencies and 2 hospice locations u Increased clinical collaboration between IRFs and Home Health Ÿ Clinical collaboration rate increased by 350 basis points over Q4 2016 Ÿ Completed TEAMWORKS initiative to extend best practices across all overlap markets. u Enhanced use of technology to further improve patient outcomes Ÿ Completed installation of ACE-IT and continued in-service upgrades Ÿ Enhanced utilization of clinical data analytics (e.g., ReAct; Sepsis Alert) Ÿ Announced formation of Post-Acute Innovation Center in collaboration with Cerner u Reduced leverage Ÿ Redeemed $320 million of convertible notes by issuing ~8.9 million shares common stock and paying cash of $0.6 million u Increased size of revolver from $600 million to $700 million and extended maturity to 2022 u Continued shareholder distributions Ÿ Repurchased 0.9 million shares of common stock for ~$38 million Ÿ Paid ~$92 million in cash dividends Ÿ Raised quarterly cash dividend per common share for fourth straight year (from $0.24 to $0.25) 

 

Encompass Health 27 GROWTH OPERATIONAL INITIATIVES CAPITAL STRUCTURE Priorities for 2018 u Expand portfolio of inpatient rehabilitation hospitals Ÿ Demographic trends driving increased demand for inpatient rehabilitation services Ÿ IRFs are best positioned to expand service offering in the progression towards site neutrality (see page 22) Ÿ Joint venture or wholly owned opportunities based on market-specific dynamics Ÿ Increase capacity at existing IRFs via bed additons u Expand portfolio of home health and hospice agencies Ÿ Demographic trends driving increased demand for skilled home health services and in-home hospice services Ÿ Home health benefiting from skilled nursing facility (“SNF”) disintermediation Ÿ Continue emphasis on: ü Increasing overlap with the Company’s inpatient rehabilitation hospitals ü Increasing market density via acquisitions in existing and contiguous home health markets Ÿ Build scale in hospice service line 

 

Encompass Health 28 CAPITAL STRUCTURE OPERATIONAL INITIATIVES u Implement rebranding and name change (see page 34) u Continue to develop and implement post-acute patient navigation tools • Post-Acute Innovation Center ü Enhanced data analytics to design post-acute clinical pathways ü Formation of post-acute networks including third-party providers u Continue to enhance clinical collaboration between the Company’s IRFs and home health locations, including TEAMWORKS initiative to extend best practices across all overlap markets u Refine and expand use of predictive data analytics to further improve patient outcomes (e.g., ReAct; Sepsis Alert) u Increase participation in alternative payment models Priorities for 2018 GROWTH u Maintain real estate ownership and balance sheet flexibility u Consider opportunistic refinancings u Continue to augment returns from investments in operations with shareholder distributions 

 

Encompass Health 29* See also the "Estimated Impact of the New Revenue Recognition Accounting Standard" on page 30.Refer to pages 106-109 for end notes. Guidance Adjusted EBITDA(10) Adjusted Earnings per Share from Continuing Operations Attributable to Encompass Health(11) Net Operating Revenues* 2018 Preliminary Guidance Net Operating Revenues* Adjusted EBITDA(10) $830 million to $850 million Adjusted Earnings per Share from Continuing Operations Attributable to Encompass Health(11) $3.25 to $3.40 $3,900 million to $3,950 million $810 million to $820 million $2.67 to $2.73 $4,150 million to $4,250 million 2017 Guidance The Company currently expects to be in the upper half of these ranges. 

 

Encompass Health 30 Expected Impact of the New Revenue Standard - Historical Periods As Reported Recast Q3-17 Q2-17 Q1-17 FY 2016 Q3-17 Q2-17 Q1-17 FY 2016 Net operating revenue (millions) $ 995.6 $ 981.3 $ 974.8 $ 3,707.2 $ 983.0 $ 967.6 $ 958.4 $ 3,646.0 Provision for doubtful accounts (millions) 12.6 13.7 16.4 61.2 — — — — Inpatient rehabilitation revenue/discharge 17,896 17,823 18,131 17,577 17,610 17,520 17,768 17,225 Home health revenue/episode 3,022 2,989 2,991 3,031 3,008 2,975 2,978 3,017 Adjusted EBITDA (millions) 204.6 209.5 200.8 793.6 No Change Adjusted EPS 0.66 0.71 0.70 2.67 No Change Estimated Impact of the New Revenue Recognition Accounting Standard Expected Impact of the New Revenue Standard - 2017 and 2018 Guidance 2017 Guidance* 2018 Guidance (in millions, except per share data) Current Recast Current Recast Net operating revenue $3,900 - 3,950 $3,840 - 3,890 $4,150 - 4,250 $4,080 - 4,190 Adjusted EBITDA 810 - 820 No change 830 - 850 No change Adjusted EPS 2.67 - 2.73 No change 3.25 - 3.40 No change u During the first quarter of 2018, Encompass Health will adopt a new accounting standard (ASC 606 - Revenue from Contracts with Customers) which clarifies the standards for recognizing revenue. u Based on the Company's current evaluation of the new standard, the expected impact to the Company will be that amounts previously presented as provision for doubtful accounts become a component of consolidated net operating revenue (both segments impacted similarly). • This will have the effect of reducing net operating revenues but will be neutral to Adjusted EBITDA and adjusted EPS. u The Company will retrospectively adopt the new standard during Q1 2018, which means previously reported full-year results for 2016 and quarterly results for 2017 will be updated to reflect the requirements of the new standard. * The Company currently expects to be in the upper half of the 2017 guidance ranges. Refer to pages 106-109 for end notes. 

 

Encompass Health 31 2018 Guidance Considerations Inpatient Rehabilitation u Estimated 0.8% increase in Medicare pricing for Q1 through Q3; ~1.25% for Q4 u Salary increase of ~3.0%; benefits increase of ~8.0% to 10.0% u Bad debt expense of 1.6% to 1.9% of net operating revenues Home Health and Hospice u Estimated 1.0% net Medicare pricing reduction for CY 2018 u Salary increase of ~3.0%; benefits increase of ~8.0% to 10.0% u Inclusive of home health and hospice acquisitions in 2018 Consolidated u Includes approximately $11 million to $13 million of operating expenses (included in corporate general and administrative expenses) associated with the rebranding and name change u Diluted share count of ~99.3 million shares u Tax rate of ~28% (includes impact from Tax Cuts and Jobs Act) 

 

Encompass Health 32 u Increased cash payments for taxes in 2018 primarily due to exhaustion of federal NOL in Q1 2017 Adjusted Free Cash Flow(12) Assumptions Reconciliations to GAAP provided on pages 94-104. Refer to pages 106-109 for end notes. Certain Cash Flow Items (millions) 2017 Estimates 2018 Assumptions • Cash interest expense (net of amortization of debt discounts and fees) ~$148 $140 to $150 • Cash payments for taxes, net of refunds ~$100 $125 to $150 • Working Capital and Other $0 to $25 $50 to $70 • Maintenance CAPEX $140 to $150 $130 to $150 • Adjusted Free Cash Flow $387 to $432 $310 to $405 u Maintenance capital expenditures in 2018 reflect completion of new home office and installation of ACE-IT offset by expenditures associated with rebranding field assets. u Working capital increase in 2018 due to expected resumption of Medicare pre-payment claims denials to historical levels 

 

Encompass Health 33 2017 2018 Estimates Assumptions Debt redemptions (borrowings), net ~$162 $ opportunistic Cash dividends on common stock(13) ~92 ~100 Common stock repurchases ~38 opportunistic ~$292 $TBD Free Cash Flow Priorities 2017 2018 Estimates Assumptions IRF bed expansions ~$30 $30 to $40 New IRFs - De novos ~80 80 to 110 - Acquisitions ~11 opportunistic - Replacement IRFs and other ~10 40 to 50 New home health and hospice acquisitions ~50 50 to 100 ~$181 $200 to $300, excluding IRF acquisitions Shareholder Distributions Growth in Core Business Debt Reduction Quarterly cash dividend currently set at $0.25 per common share ~$58 million authorization remaining as of December 31, 2017 Net redemptions in 2017 exclude ~$276 million associated with the non- cash conversion of the Convertible Senior Subordinated Notes. See the debt schedule on page 62. Refer to pages 106-109 for end notes. 

 

Encompass Health 34 Rebranding and Name Change u Both business segments — inpatient rehabilitation and home health and hospice — will fully transition to the Encompass Health branding by the end of the first quarter of 2019. Ÿ Rebranding and name change reinforce the Company’s existing strategy and position as an integrated provider of inpatient and home-based care. Ÿ Effective January 1, 2018, HealthSouth Corporation changed its name to Encompass Health Corporation, with a corresponding ticker symbol change from “HLS” to “EHC.” Ÿ Total rebranding investment estimated to be ~$25 million to $30 million, to be incurred between 2017 and 2019 2017 2018 2019 Total Operating Expenses* ~$6 million ~$11 to $13 million ~$1 to $2 million ~$18 to $21 million Capital expenditures ~$1 million ~$5 to $6 million ~$1 to $2 million ~$7 to $9 million Total rebranding investment ~$7 million ~$16 to $19 million ~$2 to $4 million ~$25 to $30 million *Included in corporate general and administrative expenses line item 

 

Encompass Health 35 • Consider acquisitions of other complementary businesses • Maintain real estate ownership and balance sheet flexibility • Quarterly cash dividends • Opportunistic share repurchases - (~$58 million authorization remaining as of December 31, 2017) Business Outlook: 2018 to 2020 • Same-store IRF growth • New-store IRF growth (de novos and acquisitions) • Same-store home health and hospice growth • New-store home health and hospice growth (acquisitions and de novos) Core Growth Strong Balance Sheet Shareholder Distributions Expansion of Service Offerings 2019 20202018 Key Operational Initiatives Ÿ Implement rebranding and name change Ÿ Develop and implement post-acute patient navigation tools Ÿ Enhance clinical collaboration between the Company’s IRFs and home health locations, including TEAMWORKS initiative to extend best practices across all overlap markets Ÿ Refine and expand use of clinical data analytics to further improve patient outcomes (e.g., ReAct; Sepsis Alert) Ÿ Increase participation in alternative payment models 

 

Encompass Health 36 Business Outlook 2018 to 2020: Revenue Assumptions • 10% to15% annual episode growth • Includes $35-$40 million per annum in agency acquisitions Volume (Includes New Stores) Inpatient Rehabilitation Home Health & Hospice Medicare Pricing Approx. 73% of Revenue Approx. 85% of Revenue FY 2018 Q417-Q318(14) FY 2019 Q418-Q319 Estimate* FY 2020 Q419-Q320 Estimate* CY 2018 Q118-Q418(14) CY 2019 Q119-Q419 Estimate* CY 2020 Q120-Q420 Estimate* Market basket update 1.0% 2.8% 2.9% 1.0% 2.8% 2.9% Healthcare reform reduction - (75) bps - - - - Coding intensity reduction - - - (0.9%) - - Expiration of rural add-on - - - (0.5%) - - Healthcare reform productivity adjustment - (80) bps (50) bps - (80) bps (50) bps Net impact - all providers 1.0% 1.25% 2.4% (0.4%) 2.0% 2.4% Impact from case mix re-weighting - - - (0.6%) - - Estimated impact to Encompass Health(15) 0.8% (1.0%) Medicare Advantage and Managed Care Pricing Approx. 19% of Revenue Approx. 14% of Revenue Expected Increases 2-4% 2-4% 2-4% 0-2% 0-2% 0-2% • 3+% annual discharge growth • 10+% annual admission growth * Estimates are based on current CMS and Congressional Budget Office projections which do not include potential changes from legislation or the CMS rule-making process. Refer to pages 106-109 for end notes. 

 

Encompass Health 37 Inpatient Rehabilitation Home Health and Hospice Business Outlook 2018 to 2020: Labor and Other Expense Assumptions Salaries and Benefits ~70% IRF Expenses ~30% Salaries and Benefits 2018 2019 2020 Salary increases 2.75-3.25% 2.75-3.25% 2.75-3.25% Benefit costs increases 8-10% 5-10% 5-10% IRF Expenses •Other operating expenses and supply costs tracking with inflation Salaries and Benefits ~85% Other Expenses ~15% Home Health and Hospice Expenses •Other operating expenses and supply costs tracking with inflation % of Salaries and Benefits Salaries ~90% Benefits ~10% 

 

Encompass Health 38 IRF-PPS Fiscal Year 2018 Final Rule: Key Provisions Company Observations Pricing: • Net pricing impact to the Company expected to be an increase of approx. 0.8% for FY 2018 (see page 36) • Because of its efficient cost structure, the Company receives very few outlier payments despite treating higher acuity patients (see page 87). Quality: • The Company will supplement existing quality reporting systems to meet the new requirements. Source: https://www.federalregister.gov/documents/2017/08/03/2017-16291/medicare-program-inpatient- rehabilitation-facility-prospective-payment-system-for-federal-fiscal CMS: • Removed All-Cause Unplanned Readmission Measure for 30 Days Post- Discharge from IRF; • Removed and replaced the Percent of Residents or Patients with Pressure Ulcers That Are New or Worsened (Short Stay) (NQF #0678) measure with a modified version entitled Changes in Skin Integrity Post-Acute Care: Pressure Ulcer/Injury beginning with the FY 2020 IRF QRP; • Added six quality measures to those publicly reported on IRF Compare; and • Finalized the data elements currently reported on the IRF-PAI that meet the definition of standardized patient assessment data for the IMPACT Act. New Quality Reporting Update to Payment Rates The final rule: • Implemented a net 1.0% market basket increase as established by the Medicare Access and CHIP Reauthorization Act (MACRA) of 2015; • Updated Case-Mix Group Relative Weights and Average Length of Stay Values; • Updated the outlier threshold; and • Updated wage index values. 60% Rule - Update to Presumptive Methodology Code List • CMS finalized certain changes to the list of codes it uses to presumptively test compliance with the 60% Rule. – The final rule adds ICD-10-CM diagnosis codes for traumatic brain injury, hip fracture, and major multiple trauma (effective beginning on or after October 1, 2017). – The final rule does not include the originally proposed removal of certain ICD-10-CM codes. 

 

Encompass Health 39 HH-PPS Calendar Year 2018 Final Rule: Key Provisions New Quality Reporting Measures Final Rule Update to 2018 Payment Rates Company Observations The final rule will: • Implement a net 1.0% market basket increase as established by the Medicare Access and CHIP Reauthorization Act (MACRA) of 2015 and • Implement year three of a three-year nominal case-mix coding intensity reduction adjustment of (0.9%). The final rule will implement the expiration of the rural add-on (0.5%), which Congress could elect to extend. CMS adopted, for the CY 2020 payment determination, three measures to meet the requirements of the IMPACT Act: • Changes in skin integrity post-acute care pressure ulcer/injury; • Application of % of residents experiencing one or more falls with major injury; and • Application of % of long-term care hospital patients with an admit and discharge functional assessment and care plan that addresses function. These finalized measures will be calculated from OASIS data. Sources: https://www.federalregister.gov/documents/2017/11/07/2017-23935/medicare-and-medicaid- programs-cy-2018-home-health-prospective-payment-system-rate-update-and-cy Proposed Home Health Groupings Model Not Finalized CMS had proposed to implement significant changes to the home health payment system beginning on January 1, 2019. These changes were known as the Home Health Groupings Model (“HHGM”). • CMS did not finalize the HHGM proposal in the 2018 final rule and indicated they will take additional time to further engage with stakeholders to move towards a system that shifts the focus from volume of services to a more patient-centered model. Payment System: • The Company will continue to engage with CMS, Congress, and other stakeholders to ensure that any change to the underlying payment system maintains access to needed home health services. Pricing: • Net pricing impact to the Company expected to be a decrease of approx. 1.0% for CY 2018 (see page 36) Quality: • The Company will supplement existing processes and systems to meet the new requirements. 

 

Encompass Health 40 Company observations and considerations with respect to the IMPACT Act: ▪ It was developed on a bi-partisan basis by the House Ways and Means and Senate Finance Committees and incorporated feedback from healthcare providers and provider organizations that responded to the Committees’ solicitation of post-acute payment reform ideas and proposals. ▪ It directs the United States Department of Health and Human Services (“HHS”), in consultation with healthcare stakeholders, to implement standardized data collection processes for post-acute quality and resource use measures. ▪ Although the IMPACT Act does not specifically call for the implementation of a new post-acute payment system, the Company believes this act will lay the foundation for possible future post-acute payment policies that would be based on patients’ medical conditions and other clinical factors rather than the setting where the care is provided. ▪ It will create additional data reporting requirements for the Company’s IRFs(16) and home health agencies. The precise details of these new reporting requirements, including timing and content, will be developed and implemented by the Centers for Medicare and Medicaid Services through the regulatory process that the Company expects will take place over the next several years. ▪ While the Company cannot quantify the potential financial effect of the IMPACT Act on Encompass Health, the Company believes any post-acute payment system that is data driven and focuses on the needs and underlying medical conditions of post-acute patients will be positive for providers who offer high-quality, cost-effective care. Encompass Health believes it is doing just that and expects this act will be positive for the Company. ▪ However, it will likely take years for the quality data to be gathered, standardized patient assessment data to be assembled and disseminated, and potential payment policies to be developed, tested and promulgated. As the nation’s largest owner and operator of inpatient rehabilitation hospitals, the Company looks forward to working with HHS, the Medicare Payment Advisory Commission and other healthcare stakeholders on these initiatives. IMPACT Act of 2014 - Enacted October 6, 2014 Source: https://www.govtrack.us/congress/bills/113/hr4994/text Refer to pages 106-109 for end notes. 

 

Encompass Health 41 Growth Encompass Health is a leader in serving the post-acute patient population and has multiple avenues available for sustained growth in both segments. Favorable demographic trends are driving increased demand. 

 

Encompass Health 42 The Company Has Multiple Avenues Available for Sustained Growth in Both Segments u The Company continues to have excellent organic growth opportunities ininpatient rehabilitation, home health, and hospice. — Track record of consistent market share gains — IRF organic growth supplemented by bed additions — Maturation of acquired home health locations u Target four to six new inpatient rehabilitation hospitals per year to complementorganic growth — De novos and acquisitions will allow entry into, and growth in, new markets. — Proven track record of success u Target $50 to $100 million per year toward home health and hospice acquisitionsto complement organic growth — Home health acquisitions and new-store growth prioritized in Encompass Health IRF markets without current overlap — Build additional scale in hospice via acquisitions and de novos 

 

Encompass Health 43 Both Segments Benefit from a Demographic Tailwind: Growth in the Medicare Beneficiary Population Projected Population of Age 65+ Age 80+Age 70-79Age 65-69 Millions • The growth rate of Medicare beneficiaries increased in 2011 to an approx. 3% CAGR as “Baby Boomers” started turning age 65. • The CAGR for the population in Encompass Health’s average patient age range is ~5%. 41% (19.0M) 43% (22.8M) 45% (27.0M) 46% (31.1M) 46% (33.8M) CAGR (Population Growth by Age) Age 2014to 2018 2018 to 2022 2022 to 2026 2026 to 2030 65-69 3.0% 2.7% 1.6% (0.1)% 70-74 5.1% 3.8% 2.6% 2.1% 75-79 4.1% 5.1% 5.0% 2.1% 80+ 1.6% 2.5% 3.6% 5.3% Total 3.3% 3.4% 3.0% 2.3% ~3% CAGR Source: www.census.gov/data/datasets/2014/demo/popproj/2014-popproj.html Baby Boomer wave reaches average age of an Encompass Health Medicare patient (~76). 

 

Encompass Health 44 1,600 1,400 1,200 1,000 800 600 400 200 0 132 127 122 117 112 107 102 97 92 87 82 77 72 2013 2014 2015 2016 2017 Projected 2018 % Increase in licensed beds 4% 18% 1% 4% 3% Total number of licensed beds 6,825 7,095 8,404 8,504* 8,851 9,120 Total number of IRFs 103 107 121 123* 127 131 Multi-faceted Inpatient Rehabilitation Growth Strategy Total IRFsNew Beds 2017 bed count increase • Gulfport, MS (33 beds) • Westerville, OH (60 beds) • Jackson, TN (48 beds) • Pearland, TX (40 beds) • Bed expansions (166 beds) 2018 projected bed count increase • Shelby County, AL (34 beds) • Hilton Head, SC (38 beds) • Murrells Inlet, SC (29 beds) • Winston-Salem, NC (68 beds) • Bed expansions (~100 beds) * 2016 total number of licensed beds and total number of IRFs includes the disposal of 61 beds at Beaumont, TX (sold June 2016) and 83 beds at Austin, TX (closed August 2016). Wholly Owned and Joint Venture s Bed Expansions De Novos Acquisitions 

 

Encompass Health 45 Disciplined Approach to New Store Growth – $7.4 Billion Medicare IRF Market – Considerations: – Market demographics – Presence of other IRFs – Geographic proximity to other Company IRFs and home health locations – Potential joint venture partners Source: MedPAC December 2016 Public Meeting presentation CA = confidentiality agreement Inpatient Rehabilitation Growth Pipeline Typical Development Pipeline Factors: • Certificate of Need process/timeline • Fair market valuation of contributed assets (joint ventures only) • Partnership complexities The Company’s Value Proposition ü CAPEX to build free-standing IRF, freeing up space formedical/surgical beds in an acute care facility for a JV partner ü Enhance the position of the acute care hospital to meetquality requirements and effectively participate in alternative payment models ü Increased acute care hospital flow-through by takingappropriate higher acuity patients faster than other post- acute settings ü Clinical collaboration between the Company’s IRFs and homehealth locations ü Proprietary rehabilitation-specific clinical information system (“ACE-IT”) integrated with acute care hospitals’ clinical information systems to facilitate patient transfers, reduce readmissions, and enhance outcomes ü Proprietary real-time performance management systems (care management, labor productivity, quality reporting, therapy analysis and expense management) to ensure appropriate clinical oversight and improve profitability ü Proven track record of efficient management of regulatoryprocess (CON, licensure, occupancy, etc.) ü Experienced transaction/integration team ü National leader in post-acute policy activities ü TeamWorks approach to sales and marketing ü Supply chain efficiencies ü Medical leadership and clinical advisory boards No. of Projects Exploratory / CA Executed 30 - 40 Actively Working 10 - 12 Near-term Actionable 4 - 6 

 

Encompass Health 46 • The Company’s IRF joint ventures began in 1991 with Vanderbilt University Medical Center. • The Company’s joint venture acute care hospital partners own equity that range from 2.5% to 50%. • 41 of 42 IRFs are consolidated joint ventures, with one accounted for under the equity method. Inpatient Rehabilitation Acute Care Joint Venture Partnerships 42* IRF joint ventures in place with major healthcare systems such as: Joint ventures with acute care hospitals establish a solid foundation for integrated delivery and alternative payment models. • Barnes-Jewish • Monmouth Medical Center (Barnabas Health) • University of Virginia Medical Center • Yuma Regional Medical Center • Vanderbilt University Medical Center • Mercy Health System • Geisinger Health System • Maine Medical Center • Martin Health System • Methodist Healthcare-Memphis Hospitals, a subsidiary of Methodist Le Bonheur Healthcare * Excludes IRF joint ventures that have been announced but were not operational as of December 31, 2017: Winston-Salem, NC; Murrells Inlet, SC; and Lubbock, TX. 

 

Encompass Health 47 De Novo IRFs and Acquisitions Investment Considerations • IRR objective of 13% (after tax) • Joint venture capitalization • Certificate of Need (“CON”) costs, where applicable • Clinical Information System (“CIS”) installation costs • Medicare certification for new hospitals (minimum of 30 patients treated for zero revenue) De Novo IRFs Operational Date Location Beds Joint Venture 2019 Lubbock, TX 40 Yes 2019 Murrieta, CA 50 Q4 2018 Winston-Salem, NC 68 Yes Q2 2018 Hilton Head, SC 38 Q1 2018 Shelby County, AL 34 Q4 2017 Pearland, TX 40 Q3 2017 Jackson, TN 48 Yes Q3 2017 Broken Arrow, OK* 40 Yes Q2 2017 Westerville, OH 60 Yes Q4 2016 Modesto, CA 50 Q3 2016 Bryan, TX* 49 Yes Q3 2016 Hot Springs, AR* 40 Yes Q2 2016 Savannah, GA* 50 Yes Q4 2015 Franklin, TN 40 Acquisitions Acquisition Date Location Beds Joint Venture Q3 2018 Murrells Inlet, SC 29 Yes Q2 2017 Gulfport, MS 33 Yes Q3 2016 Broken Arrow, OK* 22 Yes Q3 2016 Bryan, TX* 19 Yes Q1 2016 Hot Springs, AR* 20 Yes Q2 2015 Lexington, KY 232 Q2 2015 Savannah, GA* 50 Yes * An acquisition that began operations in an existing IRF or unit while a new IRF was/is constructed 

 

Encompass Health 48 CON Process (if applicable) Zoning & Design Permitting Construction OpeningGroundbreaking De Novo Costs and Timeline Capital Cost (millions) Low High Construction, design, permitting, etc. $17 $21 Land 2 3 Equipment (including CIS) 3 4 Range of a typical 40-50 bed IRF $22 $28 Pre-Opening Expenses(17) (millions) Low High Operating $0.5 $1.0 Salaries, wages, benefits 0.4 1.0 $0.9 $2.0 • Prototype includes all private rooms • Core infrastructure of building anticipates future expansion (accretive to financial returns) • Factors that impact costs/timeline: ◦ CON status ◦ State regulatory requirements ◦ Local planning and zoning approvals ◦ Hospital-specific complexities Project Start 20 months6 months to 3 years Illustrative Timeline Refer to pages 106-109 for end notes. 

 

Encompass Health 49 Littleton (05/2013) Stuart (06/2013) Altamonte Springs (10/2014) Newnan (12/2014) Middletown (12/2014) Franklin (12/2015) Modesto (10/2016) Westerville (04/2017) The Company’s average 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% 1 2 3 4 5 6 7 8 9 10 11 12 Months IRF De Novo Occupancy and EBITDA* Trends Occupancy Sustained Positive EBITDA * IRF EBITDA = earnings before interest, taxes, depreciation, and amortization directly attributable to the related hospital. 2016 occupancy 

 

Encompass Health 50 • Strong demand due to cost effectiveness of home-based care and implementation of alternative payment models • Strong organic growth from existing agencies • Located in markets with attractive demographics * Currently located in states that represent ~67% of total Medicare home health and hospice spend • Prioritization of existing home health markets • Opportunity to build scale and leverage components of existing infrastructure • Attractive partner due to quality of outcomes, data management, scale and market density, and willingness/ability to treat high acuity and/or chronic patients • Plan of care coordination with the Company’s IRFs • Care Transition Coordinators serve as representatives in transitional care activities and strategic relationships with other healthcare providers • Highly fragmented market • Prioritization of new IRF overlap markets • Proven ability to consummate and integrate acquisitions • Sustainable and replicable culture • Implementation of best practices and technology Organic Growth Home Health Acquisitions and De Novos Hospice Acquisitions and De Novos Clinical Collaboration Multi-faceted Home Health and Hospice Growth Strategy 

 

Encompass Health 51 13,000 12,000 11,000 10,000 9,000 8,000 7,000 6,000 5,000 4,000 # of Ag en ci es 1996 1998 2000 2002 2004 2006 2008 2010 2012 2014 Home Health Growth Pipeline • $18.1 billion Medicare home health market is highly fragmented with over 12,300 home health agencies. • Approx. 94% of these have annual revenue of less than $5 million. • Top 5 public companies represent approx. 20% of the Medicare market. • The Company represents 3.1% of the Medicare home health market. Prioritize acquisitions in Company IRF markets to enhance clinical collaboration Number of Home Health Agencies Over Time Cost- Based Interim Payment Systems (IPS) Prospective Payment System (PPS) The number of home health agencies is near an all-time high and presents significant consolidation opportunities. Source: MedPAC, Medicare Payment Policy - March 2017, page 231; March 2016, page 214; March 2015, page 218; March 2014, page 221; March 2013, page 194; and March 2003, page 112; MedPAC - Healthcare spending and the Medicare program, June 2006, page 131; Medicare Claims Data 

 

Encompass Health 52 Freestanding Hospital/SNF based Home Health based 4,000 3,000 2,000 1,000 0 2000 2007 2013 2014 2015 1,069 2,103 2,844 3,024 3,138807 704 578 558 547 378 443 503 510 514 Hospice Growth Pipeline • Medicare hospice market is approx. $16 billion. • 1.4 million Medicare beneficiaries received hospice services from approx. 4,200 providers in 2015. • Hospice use among Medicare beneficiaries has grown substantially in recent years, suggesting greater awareness of and access to hospice services. • Since 2000, there has been a substantial increase in the number of for-profit providers. Acquisition Strategy for Hospice • Build additional scale • Medicare focus • Home-based service offering • Strong clinical practice and clean compliance record • Highly regarded market reputation • Attractive geography and demographics • Ability to leverage existing infrastructure Hospice Providers over Time Source: MedPAC, Medicare Payment Policy, March 2017, pages 317, 319, and 324. 

 

Encompass Health 53 Alternative Payment Models 

 

Encompass Health 54 Accountable Care Organizations (“ACOs”) Medicare Shared Savings Program (MSSP) (2016 - 432 ACOs / 7.9 million Medicare beneficiaries) • Performance Year 4 (2016) results: ◦ 241 ACOs (56%) held spending below their benchmark. ▪ 107 of these ACOs reduced health costs compared to their benchmark, but did not meet the minimum savings threshold for shared savings. ◦ 191 ACOs (44%) did not reduce costs compared to their benchmark. ◦ Shared Savings Program ACOs generated total program savings of $652 million. Source: CMS/HHS press releases and public use files The Company serves as Premier ACO’s exclusive preferred home health provider. (~22,000 covered lives in north Texas and southern Oklahoma) Ÿ Receives increased referrals for Medicare home health patients from the ACO Ÿ Eligible to receive a portion of the ACO’s shared savings Ÿ Total shared savings achieved by ACO in 2016 was $12.5 million. - Ranked 2nd in savings rate out of all MSSP ACOs with >20,000 assigned beneficiaries - Met the minimum savings rate to participate in shared savings Medicare ACO Track 1+ Model (will start in 2018) • Will test a payment design that incorporates more limited downside risk than Tracks 2 or 3 (two-sided risk models) of the MSSP Next Generation ACOs (2016 - 18 ACOs / 0.5 million Medicare beneficiaries) • Initiative launched in January 2016 for ACOs that are experienced in coordinating care for populations of patients • Allows providers to assume higher levels of financial risk and reward than are available under the MSSP • Performance Year 1 (2016) results: ◦ 11 out of 18 ACOs generated savings and received shared savings of $58M. ◦ Remaining 7 ACOs generated losses and were required to pay back $20M to CMS. • Next Generation ACO participants increased to 44 in 2017. As of June 2017, there were 561 Medicare ACOs serving 9.5 million Medicare and/or Medicaid beneficiaries. Performance results so far have been mixed. 

 

Encompass Health 55 Bundled Payments How the Retrospective Models Work Ÿ The BPCI “convener” is responsible for bringing providers together to provide a continuum of services throughout an episode of care. The BPCI “awardee” is the entity that bears the financial risk and receives the shared savings from CMS. Ÿ Each participating provider in the care sequence continues to receive its traditional reimbursement from Medicare. Ÿ The sum of all payments made to each provider for selected DRGs is then retroactively reconciled to a target payment determined by CMS. Payment reconciliations are performed quarterly, typically with a 9- to 12-month lag. Ÿ Payment reconciliations: If actual spending exceeds the target, the awardee is responsible for paying a portion of the difference to CMS. If actual spending is less than the target, the awardee keeps a portion of the savings. Ÿ The convener can choose to partner with other providers in shared savings agreements and allocate the savings across the providers who participated in providing the continuum of care. Ÿ Shared savings agreements must be reviewed and approved by the Center for Medicare and Medicaid Innovation. Model 1 All acute patients (all DRGs) – Concluded December 31, 2016 – The Bundled Payments for Care Improvement (BPCI) initiative currently tests four types of bundles (i.e. “Models”): Models 2 & 3 have the most impact on post-acute providers. Model 2 Hospital plus post-acute period (selected DRGs) Model 3 Post acute only (selected DRGs) Model 4 Hospital plus readmissions (selected DRGs) Notes: Models 1, 2, and 3 are retrospective models; model 4 is a prospective model. The convener and awardee can be, but may not be, the same entity. 

 

Encompass Health 56 The Company’s Participation in BPCI Model 3 Inpatient Rehabilitation BPCI Bundle ParticipatingIRFs Bundle Length (in days) % of the Company’s Total Discharges Stroke 3 60 0.12% Simple Pneumonia 1 60 0.02% Sepsis 1 60 0.01% Double-lower extremity joint replacement 2 60 <0.01% Upper extremity joint replacement 1 60 <0.01% Total 8 0.16% Home Health BPCI Bundle ParticipatingLocations Bundle Length (in days) % of the Company’s Total Episodes Major joint replacement of the lower extremity 26 90 0.80% Spinal fusion (non-cervical) 9 60/90 0.06% Sepsis 14 90 0.06% Revision of the hip or knee 14 90 0.05% Simple pneumonia and respiratory infections 8 90 0.04% Major joint replacement of the upper extremity 8 60/90 0.04% Other respiratory 19 90 0.04% Urinary tract infection 6 90 0.04% Congestive heart failure 32 90 0.02% Chronic obstructive pulmonary disease 17 90 0.01% All other episode types 51 30/60/90 0.12% Total 204* 1.29% Note: Data based on 2016 discharges/episodes * The 204 participating locations represents a total of 79 locations participating in numerous different bundles. 

 

Encompass Health 57* These comorbidities are specific to acute care hospitals and are defined differently than IRFs’ comorbidities.Source: https://innovation.cms.gov/initiatives/cjr Acute care hospital patients are categorized by Medicare Severity Diagnosis Related Groups (“MS-DRGs”); the CJR model covers two MS-DRGs: MS-DRG 469 Major joint replacement or reattachment of lower extremity with major complications or comorbidities* MS-DRG 470 Major joint replacement or reattachment of lower extremity without major complications or comorbidities* IRF patients are categorized by Rehabilitation Impairment Categories (“RICs”); CJR model patients are a subset of two RICs: RIC 07 Lower extremity fractures (~30% are MS-DRGs 469 and 470) RIC 08 Lower extremity joint replacements (~75% are MS-DRGs 469 and 470) Since the implementation of the 60% Rule in 2007, the relative number of RIC 07 and RIC 08 patients treated in the Company’s IRFs has declined significantly. RIC % of the Company’s Medicare Discharges 2005 2007 2009 2011 2013 2015 2016 Total RIC 07 (Fractures) 13.1% 14.8% 13.6% 11.6% 10.2% 9.8% 6.5% Total RIC 08 (Replacements) 17.9% 11.8% 9.0% 7.6% 6.7% 5.5% 3.2% Comprehensive Care for Joint Replacement Model The Comprehensive Care for Joint Replacement Model (“CJR”) is a payment model for episodes of care related to knee and hip replacements under Medicare. The CJR model was a mandatory five-year model that began April 1, 2016 in 67 geographic areas. On November 30, 2017, CMS issued a Final Rule which reduced the number of geographic areas that were required to participate; 33 of the 67 geographic areas were moved to “voluntary” status. The Final Rule also canceled the Episode Payment Models and the Cardiac Rehabilitation Incentive Payment Model that were scheduled to begin on January 1, 2018. u~380 acute care hospitals are included in the 34 geographic areas that are required to participate in CJR. uEncompass Health has 25 IRFs located in these 34 mandatory markets (12 overlap with Encompass Health home health locations). uIn 2016, mandatory CJR patients in Encompass Health markets would have represented ~0.7% of total Encompass Health IRF discharges. 

 

Encompass Health 58 Medicare-certified home health agencies that provide services in the following states will be required to participate in the model: 1. Arizona 5 2. Florida 17 3. Iowa — 4. Maryland 3 5. Massachusetts 3 6. Nebraska — 7. North Carolina 6 8. Tennessee 5 9. Washington — Company Locations 39 In the calendar year 2016 HH-PPS final rule, CMS finalized a Home Health Value-Based Purchasing (“HHVBP”) Model that covers five performance years beginning January 1, 2016 and concluding on December 31, 2022. Home Health Value-Based Purchasing Model Over the long term, the Company believes it is well-positioned to benefit from a delivery system that rewards providers who are committed to providing high-quality care. • Two process measures from existing Outcome and Assessment Information Set (“OASIS”) data collection and three process measures submitted through the HHVBP portal • Seven outcome measures from existing OASIS data collection and two outcome measures from claims data • Five HHCAHPS** consumer satisfaction measures Total Performance Scores (a numeric score ranging from 0 to 100 based on each agency’s performance) will be calculated from the following set of measures* for Performance Year 2018: Performance Years Calendar Year forPayment Adjustment Maximum Payment Adjustment (-/+) 2016 2018† 3% 2017 2019 5% 2018 2020 6% 2019 2021 7% 2020 2022 8% Source: https://innovation.cms.gov/initiatives/home-health-value-based-purchasing-model * Per the CY 2018 HH Final Rule at: https://s3.amazonaws.com/public-inspection.federalregister.gov/2017-23935.pdf ** Home Health Care Consumer Assessment of Healthcare Providers and Systems ~21% of the Company’s home health Medicare revenue 1st Adjustment † Majority of Company’s locations in the nine VBP states were acquired in late 2015 or 2016; Company expects impact of ($0.3) million, or a (0.27%) payment adjustment to Medicare revenue in the nine VBP states, in 2018. 

 

Encompass Health 59 Capital Structure Encompass Health is positioned with a cost-efficient, flexible capital structure. 

 

Encompass Health 60 Debt Maturity Profile - Face Value 2017 2021 2022 2022 2023 2024 2025 $350 Senior Notes 5.75% $1,200 Senior Notes 5.75% $300 Senior Notes 5.125% $138 Drawn + $35 reserved for LC’s As of September 30, 2017* ($ in millions) $527 Available Callable beginning November 2017 Revolver Revolver Capacity $298 Term Loans Callable beginning September 2020 No significant debt maturities prior to 2022 Callable beginning March 2018 * This chart does not include ~$272 million of capital lease obligations or ~$80 million of other notes payable. See the debt schedule on page 62. 

 

Encompass Health 61 2012 2013 2014 2015 2016 Trailing 4 Quarters 1.25 1.52 2.11 3.17 3.02 2.62 S&P Moody’s Corporate Rating BB- Ba3 Outlook Stable Stable Revolver Rating BB+ Baa3 Senior Notes Rating B+ B1 Financial Leverage and Liquidity (1) Liquidity Credit Ratings (billions) Leverage Ratio(18) Total Debt 3.2x September 30, 2017 December 31, 2016 Cash Available $ 67.6 $ 40.5 Revolver $ 700.0 $ 600.0 Less: - Draws (138.0) (152.0) - Letters of Credit (35.4) (33.3) Available $ 526.6 $ 414.7 Total Liquidity $ 594.2 $ 455.2 2.5x Reconciliations to GAAP provided on pages 94-104. Refer to pages 106-109 for end notes. See also the debt schedule on page 62. 

 

Encompass Health 62 Debt Schedule Reconciliations to GAAP provided on pages 94-104. Change in September 30, December 31, Debt vs. ($millions) 2017 2016 YE 2016 Advances under $700 million revolving credit facility, September 2022 - LIBOR +150bps $ 138.0 $ 152.0 $ (14.0) Term loan facility, September 2022 - LIBOR +150bps 298.3 421.2 (122.9) Bonds Payable: 5.125% Senior Notes due 2023 295.7 295.3 0.4 5.75% Senior Notes due 2024 1,193.7 1,193.2 0.5 5.75% Senior Notes due 2025 344.3 343.9 0.4 2.0% Convertible Senior Subordinated Notes due 2043 — 275.7 (275.7) Other notes payable 80.1 55.8 24.3 Capital lease obligations 272.3 279.3 (7.0) Long-term debt $ 2,622.4 $ 3,016.4 $ (394.0) Debt to Adjusted EBITDA 3.2x 3.8x 

 

Encompass Health 63 39 Lease Building and Land A CON is a regulatory requirement in some states and federal jurisdictions that require state authorization prior to proposed acquisitions, expansions, or construction of new hospitals. 59 Own Building and Land 29 Own Building Only IRF Real Estate Portfolio 127 Inpatient Rehabilitation Hospitals: 8,851 Licensed Beds 4,499 Licensed Beds in CON States 4,352 Licensed Beds in Non-CON States 1 of the 127 IRFs is nonconsolidated. For that IRF, the Company owns the building only. The Company’s licensed bed count does not include the 51 beds associated with the nonconsolidated IRF. As of December 31, 2017 

 

Encompass Health 64 Options Holder – The right (but not the obligation) to sell for cash up to 1/3 of the Rollover Shares to the parent after 1/1/18; 2/3 after 1/1/19; and all outstanding Rollover Shares after 1/1/20 Company – The right (but not the obligation) to purchase for cash all or any portion of the Rollover Shares after 1/1/20 upon 20 days prior written notice Valuation Fair value of the Rollover Shares is determined using the product of Home Health Holdings’ EBITDA for the trailing 12-month period and a median market price multiple based on a basket of public home health companies and recent transactions, less the current balance of the intracompany note(s) to the parent. As of September 30, 2017, the value of the Rollover Shares was ~$194 million. In connection with the 2014 acquisition of Encompass Home Health and Hospice: • Certain members of that management team rolled a portion of their pre- acquisition equity into the post-acquisition entity (“Home Health Holdings”) resulting in a 16.7% ownership interest (the “Rollover Shares”). • Home Health Holdings was capitalized with a promissory note to the parent company totaling ~$385 million (equal to 5.5x the segment’s 2014 EBITDA). This was done to provide the opportunity for leveraged returns on the equity, thereby mimicking a private equity transaction structure. • To the extent Home Health Holdings needs cash (e.g., acquisitions, capex, etc.), such amounts may be added to the principal amount of the note or via the creation of new notes. Cash generated from the operations of Home Health Holdings may be used to pay interest and principal on the note(s). Overview of Rollover Shares Held by Members of the Home Health and Hospice Management Team Background Home Health Holdings Rollover Shares 16.7% 

 

Encompass Health 65 Information Technology Encompass Health utilizes information technology to improve patient care and generate operating efficiencies. 

 

Encompass Health 66 IRF Clinical Information System (“CIS”): Improved Patient Safety and Streamlined Operational Efficiencies Pre-Admission Assessment & Approval Discharge Planning and Patient Education •Patient History •Problems and Diagnoses •Orders and Results •Plan of Care •Workflow Alerts and Reminders •Treatment and Interventions Document Imaging Charge and Registration Services •Registration •Census •Coding •Billing Quality Reporting •Uniform Data Systems •Clinical Data Warehouse •Clinical Intelligence Referral Hospitals Ancillary Services Clinical Notes • Physician • Nursing • Therapy • Care Mgmt. Integrated and Bar-coded Point of Care Medication Administration Treatment Plan • Computerized Physician Order Entry ("CPOE") • Clinical Decision Support ("CDS") Coordinate Care and Engage Patients 

 

Encompass Health 67 IRF Proprietary Management System: Beacon 

 

Encompass Health 68 Homecare Homebase (“HCHB”) was born out of the Company’s operating model; HCHB is a leading IT platform provider in the home health and hospice industry. Optimization of capabilities in leading-edge technology embedded in culture, driving superior clinical, operational, and financial outcomes. Home Health and Hospice Information System: Homecare Homebase Clinical • HCHB manages the entire patient workflow and provides field clinicians with access to patient records, diagnostic information, and notes from prior visits via a mobile application. • Real-time, customized feedback and instructions provided on-site • Enhances patient data capture and database management which aids in the development of algorithms that can improve the plan of care Sales • Provides real-time market intelligence to sales area managers, allowing them to quickly identify the most valuable referral sources • Specialty programs integrate individual physician protocols into HCHB. – Creates loyalty and incentives for physicians and facilities, generating additional future referrals • Web-based portal allows referring physicians to easily monitor the care and progress of patients and to sign orders electronically. Compliance • Field clinicians are required to adhere to clinical protocols and physician orders, ensuring that proper regulatory and compliance procedures are followed. • Internal branch-level audits completed three times a year – HCHB-generated outputs reviewed by management to identify any branches requiring additional oversight • Compliance program also involves extensive internal training Management and Operations • Best-in-class data management and reporting ensures managers have access to relevant data needed to make correct decisions. • Rules-based algorithms ensure accountability by escalating tasks and notifying management when processes are delayed. • Seamless billing with processes in place to ensure claim completeness 

 

Encompass Health 69 Operational Metrics 

 

Encompass Health 70 Q3 YTD 2017 •Salaries and Benefits includes group medical costs and is impacted by staffing levels based on patient volumes. ◦ Salaries and Benefits in the first nine months of 2017 were impacted by planned increases in full-time equivalents (staffing increases at former Reliant IRFs; the ramping up of new IRF) and salary and benefit cost increases. •IRF-related Expenses includes other operating expenses (excluding loss on disposal or impairment of assets), supplies, and occupancy costs. •Provision for Doubtful Accounts is impacted by reserve activity related to the level of pre-payment denials by Medicare Administrative Contractors. (see page 71) •Employees per Occupied Bed (“EPOB”) is calculated by dividing the number of full-time equivalents, including an estimate of full-time equivalents from the utilization of contract labor, by the number of occupied beds during each period. The number of occupied beds is determined by multiplying the number of licensed beds by the Company’s occupancy percentage. Salaries and Benefits IRF-Related Expenses Provision for Doubtful Accounts 47.9 20.7 1.1 48.3 20.7 1.3 49.4 20.9 1.7 49.4 20.6 1.9 50.3 20.6 1.6 2013 2014 2015 2016 201 2013 2014 2015 2016 2013 2014 2015 2016 IRF Operational Metrics: Expense Efficiencies 3.44 3.40 3.41 3.44 3.46 EPOB (Percent of Net Operating Revenues) Q3 YTD 2017 Q3 YTD 2017 

 

Encompass Health 71 Pre-Payment Claims Denials - Inpatient Rehabilitation Segment Impact to Income Statement Period New Denials Collections of Previously Denied Claims Bad Debt Expense for New Denials Update of Reserve for Prior Denials (In Millions) Q3 2017 $7.4 $(6.2) $2.2 $— Q2 2017 16.5 (7.7) 4.9 — Q1 2017 19.0 (5.9) 5.7 — Q4 2016 17.8 (4.4) 5.4 0.5 Q3 2016 15.7 (8.5) 4.6 — Q2 2016 18.7 (4.9) 4.6 — Q1 2016 22.7 (8.4) 6.0 — Q4 2015 22.5 (4.1) 5.6 (1.3) Q3 2015 22.0 (4.1) 5.9 (1.1) Q2 2015 18.2 (3.8) 4.9 — Q1 2015 16.3 (3.0) 4.2 — Impact to Balance Sheet Sept. 30, 2017 Dec. 31, 2016 Dec. 31, 2015 (In Millions) Pre-payment claims denials $ 173.0 $ 159.7 $ 114.8 Recorded reserves (51.9) (47.9) (31.2) Net accounts receivable from pre-payment claims denials $ 121.1 $ 111.8 $ 83.6 Background • For several years, under programs designated as “widespread probes,” certain Medicare Administrative Contractors (“MACs”) have conducted pre- payment claim reviews and denied payment for certain diagnosis codes. • Encompass Health appeals most denials. On claims it takes to an administrative law judge (“ALJ”), Encompass Health historically has experienced an approximate 70% success rate. – MACs identify medical documentation issues as a leading basis for denials. – Encompass Health’s investment in clinical information systems and its medical services department has further improved its documentation and reduced technical denials. – However, MACs and other HHS contractors continue to issue denials without regulatory basis. • By statute, ALJ decisions are due within 90 days of a request for hearing, but appeals are taking years. HHS has implemented rule changes to address the backlog of appeals, but their effect is uncertain. • In 2016, a federal court ordered HHS to eliminate the backlog by the end of CY 2020. HHS continues to object that it cannot clear the backlog in the timeframe established by the court. Although HHS remains bound by the order, the courts are considering how HHS will comply. • All Medicare providers continue to experience delays. The backlog is growing because the ALJs receive one year’s worth of appeals every four to six weeks, according to HHS. – Currently, ALJs are hearing Encompass Health appeals from claims denied up to seven years ago. • In summer 2017, CMS announced the Targeted Probe and Educate (“TPE”) initiative. For more information regarding TPE, see https://www.cms.gov/ Research-Statistics-Data-and-Systems/Monitoring-Programs/Medicare-FFS- Compliance-Programs/Medical-Review/Targeted-Probe-and-EducateTPE.html • Effective February 2018, Palmetto GBA will assume responsibilities for Cahaba’s MAC jurisdiction. See announcement from CMS at https:// www.cms.gov/Medicare/Medicare-Contracting/Medicare-Administrative- Contractors/Downloads/JurisdictionJAwardFactSheet-09082017.pdf Encompass Health reserves pre-payment claim denials via the provision for doubtful accounts upon notice from a MAC a claim is under review. The Company currently has 75 hospitals under Cahaba’s MAC jurisdiction. 

 

Encompass Health 72 Inpatient Rehabilitation Operational and Labor Metrics * The decrease in licensed beds from Q1 2016 to Q2 2016 was due to the sale of the IRF in Beaumont, TX (61 beds). Refer to pages 106-109 for end notes. Q3 Q2 Q1 Q4 Q3 Q2 Q1 Full Year 2017 2017 2017 2016 2016 2016 2016 2016 (In Millions) Net patient revenue-inpatient $ 768.6 $ 762.9 $ 766.2 $ 740.9 $ 724.1 $ 721.2 $ 719.4 $ 2,905.5 Net patient revenue-outpatient and other revenues 26.2 27.1 26.3 26.7 27.6 31.4 29.8 115.6 Net operating revenues $ 794.8 $ 790.0 $ 792.5 $ 767.6 $ 751.7 $ 752.6 $ 749.2 $ 3,021.1 (Actual Amounts) Discharges(19) 42,948 42,805 42,259 41,474 41,368 41,365 41,098 165,305 Net patient revenue per discharge $ 17,896 $ 17,823 $ 18,131 $ 17,864 $ 17,504 $ 17,435 $ 17,505 $ 17,577 Outpatient visits 138,689 153,415 152,454 154,311 158,981 164,761 162,649 640,702 Average length of stay 12.8 12.7 12.9 12.8 12.7 12.6 12.9 12.8 Occupancy % 68.2% 69.3% 71.0% 67.8% 67.8% 68.2% 68.9% 67.8% # of licensed beds* 8,748 8,641 8,528 8,504 8,441 8,430 8,481 8,504 Occupied beds 5,966 5,988 6,055 5,766 5,723 5,749 5,843 5,766 Full-time equivalents (FTEs)(20) 20,740 20,474 20,254 19,930 19,663 19,503 19,352 19,612 Contract labor 235 251 260 245 241 205 194 221 Total FTE and contract labor 20,975 20,725 20,514 20,175 19,904 19,708 19,546 19,833 EPOB(21) 3.52 3.46 3.39 3.50 3.48 3.43 3.35 3.44 

 

Encompass Health 73 Home Health and Hospice Operational Metrics Refer to pages 106-109 for end notes. Q3 Q2 Q1 Q4 Q3 Q2 Q1 Full Year 2017 2017 2017 2016 2016 2016 2016 2016 (In Millions) Net home health revenue $ 181.2 $ 172.9 $ 165.3 $ 165.2 $ 162.0 $ 157.1 $ 150.9 $ 635.2 Net hospice and other revenue 19.6 18.4 17.0 17.1 13.1 11.0 9.7 50.9 Net operating revenues $ 200.8 $ 191.3 $ 182.3 $ 182.3 $ 175.1 $ 168.1 $ 160.6 $ 686.1 Home Health: (Actual Amounts) Admissions(22) 31,471 30,823 30,810 27,957 27,239 25,753 25,763 106,712 Recertifications 24,396 22,568 20,546 21,422 20,888 20,432 19,453 82,195 Episodes 53,757 52,101 49,260 49,253 46,866 45,774 43,844 185,737 Average revenue per episode $ 3,022 $ 2,989 $ 2,991 $ 3,023 $ 3,032 $ 3,033 $ 3,035 $ 3,031 Episodic visits per episode 17.7 18.1 18.7 18.4 19.0 18.9 19.1 18.8 Total visits 1,101,109 1,095,225 1,070,356 1,033,502 1,001,021 967,968 937,804 3,940,295 Cost per visit $ 76 $ 73 $ 75 $ 76 $ 75 $ 73 $ 73 $ 74 Hospice: Admissions(23) 1,273 1,114 1,128 996 832 785 724 3,337 Patient days 123,491 113,028 108,717 104,183 83,628 71,277 63,431 322,519 Revenue per day $ 159 $ 162 $ 157 $ 164 $ 157 $ 154 $ 153 $ 158 

 

Encompass Health 74 Payment Sources (Percent of Revenues) Inpatient Rehabilitation Segment Home Health and Hospice Segment Consolidated Q3 Q3 Q3 9 Months Full Year 2017 2016 2017 2016 2017 2016 2017 2016 2016 Medicare 73.3% 73.3% 85.2% 81.8% 75.7% 74.8% 75.3% 75.0% 75.2% Medicare Advantage 8.1% 7.6% 9.6% 8.8% 8.4% 7.9% 8.7% 7.9% 7.9% Managed care 10.7% 11.4% 3.9% 4.5% 9.4% 10.1% 9.6% 9.9% 9.8% Medicaid* 3.4% 3.0% 1.1% 4.7% 2.9% 3.3% 2.8% 3.3% 3.2% Other third-party payors 1.6% 1.8% —% —% 1.3% 1.5% 1.3% 1.4% 1.4% Workers’ compensation 0.9% 1.0% —% —% 0.7% 0.8% 0.7% 0.8% 0.8% Patients 0.6% 0.6% 0.1% 0.1% 0.5% 0.5% 0.5% 0.5% 0.5% Other income 1.4% 1.3% 0.1% 0.1% 1.1% 1.1% 1.1% 1.2% 1.2% Total 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% 100.0% * In Q4 2016, the home health and hospice segment sold its pediatric home health assets. As a result, the segment’s percentage of Medicaid has declined. 

 

Encompass Health 75 Industry Structure 

 

Encompass Health 76 Health Consumption Spending*: $2,840. 7 Overall Healthcare Spending (billions) Source: Centers for Medicare & Medicaid Services, National Health Expenditure Data (Historical), Table 2 - 2015 * Excludes Net Cost of Health Insurance National Healthcare Spending: $3,205.6 billion in 2015 Personal Healthcare: $2,717. 2 $154.7 Investment $42.6 Government Administration $80.9 Government Public Health $432.0 Retail of Medical Products $88.8 Home Health Care $163.3 Other Health, Residential and Personal Care $840.2 Professional Services $156.8 Nursing Care Facilities and Continuing Care Retirement Communities $1,036.1 Hospital CareIncludes Inpatient Rehabilitation, Long-Term Care Hospitals 

 

Encompass Health 77Source: Centers for Medicare & Medicaid Services, Medicare Trustee’s Report July 2016 – page 10; and MedPAC, Medicare Payment Policy, March 2017 - pages 197, 231, 257, 289, and 317 Medicare 2015 Spending = $647.6 Billion $ 29.8B Skilled Nursing $141.7B Inpatient Hospital $70.3B Physician Payments $46.5B Outpatient Hospital $18.1B Home Health $15.9B Hospice $63.5B Other Services $172.3B Medicare Managed Care $89.5B Outpatient Rx $7.4B (1%) Inpatient Rehabilitation Hospitals (Included in Inpatient Hospitals) 14% 3% 7% 10% 11% 26% 22% Medicare Part A Medicare Part B Medicare Parts A&B Medicare Part C Medicare Part D 5% Inpatient hospital includes spending for acute care hospitals along with inpatient rehabilitation and long-term acute care hospital services. In 2015, Medicare spent $7.4 billion and $5.3 billion, respectively for inpatient rehabilitation and long-term acute care hospital services. 2% 

 

Encompass Health 78 Preventive Routine health care (screenings, check- ups, patient counseling) to prevent illnesses, disease, or other health problems. Home health and care management services to prevent or reduce acute admissions. Continuum of Healthcare Services Acute Medical treatment of diseases for which a patient is treated for a brief but severe episode of illness Ambulatory Medical care delivered on an outpatient basis (blood tests, X- rays, endoscopy, certain biopsies, certain surgical procedures) Post-Acute Medical care provided after a period of acute care (long-term acute care, inpatient rehabilitation, skilled nursing, home health) Palliative Medical care  that is focused on providing relief from the symptoms and stress of a serious illness (hospice) 

 

Encompass Health 79 Post-Acute Care Services Acute Care Hospital Home Health Long-Term Acute Care Hospital Inpatient Rehabilitation Hospital Skilled Nursing Facility Discharge Medicare Spending (billions) $5.3 $7.4 $29.8 $18.1* # of Discharges ~131,000 ~381,000 ~2,400,000 ~3,500,000 Length of Stay 26.6 days 12.7 days 38.5 days N/A # of Providers ~430 ~1,200 ~15,000 ~12,300 Facility Ownership Mix** For-Profit (79%) Non-Profit (17%) Gov’t (4%) For-Profit (30%) Non-Profit (58%) Gov’t (12%) For-Profit (70%) Non-Profit (24%) Gov’t (6%) For-Profit (78%) Non-Profit (22%) Free-standing vs. Hospital Based N/A Free-Standing (22%)Hospital Based (78%) Free-Standing (95%) Hospital Based (5%) Free-Standing (85%) Hospital Based (15%) Rural vs. Urban** Urban (95%)Rural (5%) Urban (86%) Rural (14%) Urban (72%) Rural (28%) Urban (83%) Rural (17%) (Lowest Acuity)(Highest Acuity) Source: MedPAC, Medicare Payment Policy, March 2017 - pages 197, 201, 216, 217, 231, 247, 257, 270, 271, 289, 298, and 300; MedPAC, Health Care Spending and the Medicare Program, June 2017 - pages 121 * Not all home health spending occurs as a post-acute service. ** Facility Ownership Mix / Rural vs. Urban - home health data represents freestanding agencies only. 

 

Encompass Health 80 $35 $30 $25 $20 $15 $10 $5 $0 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 Medicare Spending on Post-Acute Services Post-Acute Settings 2015 Medicare Margin** Projected 2017 Medicare Margin** 12.6% 10.6% 15.6% 13.7% 13.9% 14.3% 4.6% 5.4% Skilled nursing facilities Home health agencies* Inpatient rehabilitation hospitals Long-term acute care hospitals Inpatient rehabilitation spending (% of total Medicare spending) 6 3 0 (P er ce nt ) 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 1.8 2.1 2.2 2.1 1.9 1.5 1.4 1.3 1.2 1.2 1.2 1.2 1.2 1.2 1.1 3.2 3.6 3.6 3.5 3.7 3.2 3.6 3.6 3.8 3.7 3.4 3.3 3.1 2.9 2.8 Home health spending* (% of total Medicare spending) Total Medicare Spending on Post-Acute Services ~$61 billion in 2015 Source: MedPAC, Medicare Payment Policy, March 2017 – pages 197, 198, 231, 232, 257, 258, 289, 290, and 291; MedPAC, Health Care Spending and the Medicare Program, June 2017 – page 112 * Not all home health spending occurs as a post-acute service. ** 2015 Medicare Margin / Projected 2017 Medicare Margin - home health data represents freestanding agencies only. 

 

Encompass Health 81 Different Levels of Services Inpatient Rehabilitation Hospital Nursing Home Average length of stay = 12.7 days Average length of stay = 38.5 days Discharge to community = 76.0% Discharge to community = 38.8% Requirements: Requirements: IRFs must also satisfy regulatory/policy requirements for hospitals, including Medicare hospital conditions of participation. No similar requirement; Nursing homes are regulated as nursing homes only All patients must be admitted by a rehab physician. No similar requirement Rehab physicians must re-confirm each admission w/n 24 hours. No similar requirement All patients, regardless of diagnoses/condition, must demonstrate need and receive at least three hours of daily intensive therapy. No similar requirement All patients must see a rehabilitation physician “in person” at least three times weekly. No similar requirement; some SNF patients may go a week or longer without seeing a physician, and often a non- rehabilitation physician. IRFs are required to provide 24 hour, 7 days per week nursing care; many nurses are RNs and rehab nurses. No similar requirement IRFs are required to use a coordinated interdisciplinary team approach led by a rehab physician; includes a rehab nurse, a case manager, and a licensed therapist from each therapy discipline who must meet weekly to evaluate/discuss each patient’s case. No similar requirement; Nursing homes are not required to provide care on a interdisciplinary basis and are not required to hold regular meetings for each patient. IRFs are required to follow stringent admission/coverage policies and must carefully document justification for each admission; further restricted in number/type of patients (60% Rule). Nursing homes have comparatively few policies governing the number or types of patients they treat. Source: MedPAC, Medicare Payment Policy, March 2017 - pages 208, 216, 217, 271, and 275 

 

Encompass Health 82 Supply of IRFs is Relatively Stable Average Annual Change Share of Medicare DischargesType of IRF 2004 2006 2008 2010 2013 2014 2015 2006-2013 2013-2015 All IRFs 100% 1,221 1,225 1,202 1,179 1,161 1,177 1,182 -0.8% 0.9% Urban 92 1,024 1,018 1,001 981 977 1,013 1,020 -0.6 2.2 Rural 8 197 207 201 198 184 164 162 -1.7 -6.2 Freestanding 48 217 217 221 233 243 251 262 1.6 3.8 Hospital based 52 1,004 1,008 981 946 918 926 920 -1.3 0.1 Nonprofit 42 768 758 738 729 677 681 681 -1.6 0.3 For profit 50 292 299 291 294 322 338 352 1.1 4.6 Government 7 161 168 173 156 155 149 138 -1.1 -5.6 Source: MedPAC, Medicare Payment Policy, March 2017 - page 270 

 

Encompass Health 83 Inpatient Rehabilitation Sector Margins Share of Medicare discharges Margins Type of IRF 2015 2004 2006 2008 2010 2012 2013 2014 2015 All IRFs 100% 16.7% 12.5% 9.3% 8.6% 11.2% 11.5% 12.5% 13.9% Urban 92 17.0 12.8 9.6 9.0 11.6 11.9 12.9 14.2 Rural 8 13.2 10.0 6.9 4.7 6.5 6.0 6.4 8.6 Freestanding 48 24.7 17.5 18.2 21.4 23.9 24.6 25.3 26.7 Hospital based 52 12.2 9.9 3.9 -0.6 0.6 -0.1 1.1 2.0 Nonprofit 42 12.8 10.9 5.3 2.1 2.4 1.2 2.3 3.6 For profit 50 24.4 16.3 16.9 19.6 22.9 23.6 24.0 25.0 Government 7 N/A N/A N/A N/A N/A N/A N/A N/A Number of beds 1 to 10 2 3.7 -3.6 -4.9 -10.3 -6.8 -11.3 -10.4 -7.8 11 to 24 22 10.5 7.3 1.2 -3.3 -1.3 -0.8 -0.2 -0.5 25 to 64 47 18.3 13.7 10.1 10.6 12.2 13.2 14.4 16.1 65 or more 28 21.5 17.8 17.3 17.5 21.0 20.0 20.7 22.7 Source: MedPAC, Medicare Payment Policy, March 2017 - page 280 

 

Encompass Health 84 Inpatient Rehabilitation Standardized Comparison of Costs Type of IRF   Median Standardized Cost Per Discharge All IRFs $14,960 Hospital based 15,847 Freestanding 11,436 Nonprofit 15,574 For profit 12,960 Government 16,601 Urban 14,608 Rural 17,724 Number of beds 1 to 10 18,085 11 to 24 16,169 25 to 64 13,619 65 or more 11,621 Quartile Characteristic Low Cost High Cost Percent: Hospital based 36% 94% Freestanding 64 6 Nonprofit 29 59 For profit 67 23 Government 4 18 Urban 93 71 Rural 7 29 Median Medicare Margin: All 28.5% -22.0% Hospital based 22.1 -22.0 Freestanding 32.0 -25.0 Median: Number of beds 50 17 Occupancy rate 74% 49% Case-mix index 1.30 1.23 Median costs per discharge: All $11,124 $19,443 Hospital based 11,756 19,434 Freestanding 10,610 19,881 Median standardized costs per discharge are lower for freestanding IRFs and larger facilities. High margin IRFs (both hospital-based and freestanding) are concentrated in the low-cost quartile of standardized costs. Source: MedPAC, Medicare Payment Policy, March 2017 - page 278 and 279 

 

Encompass Health 85 “60% Rule”: Medicare Regulation for IRFs 1983 1983: 75% Rule established – Requires 75% of IRF patients to have a qualifying condition if the IRF is to maintain reimbursement on a “cost plus” basis vs. “prospective” ( i.e., fixed) basis. 2002 2004 2007 2002: IRF reimbursement transitions to prospective payment system (“PPS”) 2002: CMS suspends 75% Rule implementation 2004: “New” 75% Rule initiated with a “new” list of “qualifying conditions” 2007: 75% Rule permanently changed to “60% Rule” with passage of “Medicare, Medicaid & SCHIP Extension Act of 2007” Paid for through a Medicare price rollback & 18-month freeze from 4/1/2008 to 9/30/2009 The 60% Rule requires at least 60% of all patients admitted must have at least one medical diagnosis or functional impairment from a list of 13 compliant conditions (a.k.a. “compliant conditions” or “CMS-13”). 

 

Encompass Health 86 1. Stroke 2. Brain injury 3. Amputation 4. Spinal cord 5. Fracture of the femur 6. Neurological disorder 7. Multiple trauma 8. Congenital deformity 9. Burns IRF Qualifying Conditions 1. Stroke 2. Brain injury 3. Amputation 4. Spinal cord 5. Fracture of the femur 6. Neurological disorder 7. Multiple trauma 8. Congenital deformity 9. Burns 10. Osteoarthritis (after less intensive setting) 11. Rheumatoid arthritis (after less intensive setting) 12. Joint replacement 13. Systemic vasculidities (after less-intensive setting) Original Qualifying Conditions Current Qualifying Conditions ■ Bilateral ■ Age ≥ 85 ■ Body Mass Index >50 10. Polyarthritis (includes “joint replacement”) Became 

 

Encompass Health 87 Inpatient Rehabilitation Outlier Payments(7) Refer to pages 106-109 for end notes. More Efficient Less Outlier Observations: • 10% of IRFs receive 50% of the outlier payments; none of the 10% are Encompass Health IRFs. • The Company receives 1.7% of the IRF outlier payments despite treating approx. 29% of the Medicare patients/discharges. • As a result of outlier payments, CMS pays the Company approx. $822 less per discharge than other providers. • Capping the IRF industry outlier payments at 10% of each IRF’s total Medicare payments could save Medicare approx. $632 million over 10 years. # of IRFs Total Outlier Payments Avg Outlier Payment per Discharge IRF Deciles Encompass Health Non- Encompass Health Total Encompass Health Non- Encompass Health Total % Encompass Health Non- Encompass Health Total 90-100 — 114 114 $ — $ 126,369,880 $ 126,369,880 50.5% N/A $ 2,733 $ 2,733 80-90 1 113 114 $ 358,714 $ 47,373,108 $ 47,731,822 19.1% $ 435 $ 1,475 $ 1,449 70-80 1 113 114 $ 218,625 $ 28,361,135 $ 28,579,760 11.4% $ 305 $ 921 $ 907 60-70 3 111 114 $ 454,703 $ 18,001,296 $ 18,455,999 7.4% $ 192 $ 512 $ 491 50-60 9 105 114 $ 941,985 $ 11,092,159 $ 12,034,144 4.8% $ 105 $ 367 $ 307 40-50 9 105 114 $ 574,291 $ 7,217,299 $ 7,791,590 3.1% $ 63 $ 279 $ 223 30-40 16 98 114 $ 773,886 $ 4,404,167 $ 5,178,053 2.1% $ 48 $ 178 $ 126 20-30 24 90 114 $ 631,125 $ 2,437,454 $ 3,068,579 1.2% $ 26 $ 114 $ 67 10-20 34 80 114 $ 359,168 $ 821,588 $ 1,180,756 0.5% $ 11 $ 44 $ 23 0-10 26 88 114 $ 12,917 $ 50,396 $ 63,313 —% $ 1 $ 2 $ 1 Totals 123 1,017 1,140 $ 4,325,414 $ 246,128,482 $ 250,453,896 100.0% 

 

Encompass Health 88 Segment Operating Results 

 

Encompass Health 89 Inpatient Rehabilitation Segment Adjusted EBITDA Q3 Q2 Q1 Q4 Q3 Q2 Q1 Full Year 2017 2017 2017 2016 2016 2016 2016 2016 Net operating revenues: (In Millions) Inpatient $ 768.6 $ 762.9 $ 766.2 $ 740.9 $ 724.1 $ 721.2 $ 719.4 $ 2,905.5 Outpatient and other 26.2 27.1 26.3 26.7 27.6 31.4 29.8 115.6 Total segment revenue 794.8 790.0 792.5 767.6 751.7 752.6 749.2 3,021.1 Less: Provision for doubtful accounts (11.3) (12.4) (14.7) (13.2) (13.7) (14.5) (15.6) (57.0) Net operating revenues less provision for doubtful accounts 783.5 777.6 777.8 754.4 738.0 738.1 733.6 2,964.1 Operating expenses: Salaries and benefits (403.2) (394.3) (398.2) (386.2) (371.2) (366.1) (369.9) (1,493.4) % of revenue 50.7% 49.9% 50.2% 50.3% 49.4% 48.6% 49.4% 49.4% Other operating expenses(a) (117.4) (112.9) (111.8) (109.8) (110.1) (106.8) (104.8) (431.5) Supplies (33.1) (33.8) (33.7) (32.7) (31.9) (31.8) (32.4) (128.8) Occupancy costs (15.7) (15.5) (15.1) (15.2) (15.0) (15.4) (15.6) (61.2) (166.2) (162.2) (160.6) (157.7) (157.0) (154.0) (152.8) (621.5) % of revenue 20.9% 20.5% 20.3% 20.5% 20.9% 20.5% 20.4% 20.6% Equity in nonconsolidated affiliates 1.9 1.8 1.9 2.4 2.3 2.2 2.2 9.1 Other income 1.0 0.9 1.0 0.8 0.8 0.7 0.6 2.9 Noncontrolling interests (16.7) (15.4) (16.5) (16.1) (14.3) (16.8) (16.8) (64.0) Segment Adjusted EBITDA $ 200.3 $ 208.4 $ 205.4 $ 197.6 $ 198.6 $ 204.1 $ 196.9 $ 797.2 In arriving at Adjusted EBITDA, the following was excluded: (a) Loss (gain) on disposal of assets $ 3.1 $ 0.8 $ (0.4) $ 2.0 $ 1.6 $ 0.2 $ 0.5 $ 4.3 Reconciliations to GAAP provided on pages 94-104. 

 

Encompass Health 90 Home Health and Hospice Segment Adjusted EBITDA Q3 Q2 Q1 Q4 Q3 Q2 Q1 Full Year 2017 2017 2017 2016 2016 2016 2016 2016 Net operating revenues: (In Millions) Home health revenue $ 181.2 $ 172.9 $ 165.3 $ 165.2 $ 162.0 $ 157.1 $ 150.9 $ 635.2 Hospice revenue 19.6 18.4 17.0 17.1 13.1 11.0 9.7 50.9 Total segment revenue 200.8 191.3 182.3 182.3 175.1 168.1 160.6 686.1 Less: Provision for doubtful accounts (1.3) (1.3) (1.7) (1.3) (1.1) (0.9) (0.9) (4.2) Net operating revenues less provision for doubtful accounts 199.5 190.0 180.6 181.0 174.0 167.2 159.7 681.9 Operating expenses(a) Cost of services (93.5) (88.7) (89.0) (89.7) (86.8) (81.6) (78.4) (336.5) % of revenue 46.6% 46.4% 48.8% 49.2% 49.6% 48.5% 48.8% 49.0% Support and overhead costs (68.9) (67.7) (66.8) (62.7) (59.5) (58.0) (57.0) (237.2) % of revenue 34.3% 35.4% 36.6% 34.4% 34.0% 34.5% 35.5% 34.6% (162.4) (156.4) (155.8) (152.4) (146.3) (139.6) (135.4) (573.7) % of revenue 80.9% 81.8% 85.5% 83.6% 83.6% 83.0% 84.3% 83.6% Equity in net income of nonconsolidated affiliates 0.2 0.2 0.2 0.1 0.2 0.2 0.2 0.7 Noncontrolling interests (2.5) (1.0) (1.1) (0.7) (2.1) (1.8) (1.9) (6.5) Segment Adjusted EBITDA $ 34.8 $ 32.8 $ 23.9 $ 28.0 $ 25.8 $ 26.0 $ 22.6 $ 102.4 In arriving at Adjusted EBITDA, the following was excluded: (a) Gain on disposal of assets $ (0.1) $ — $ (0.1) $ (3.3) $ — $ — $ (0.3) $ (3.6) Reconciliations to GAAP provided on pages 94-104. 

 

Encompass Health 91 Q3 2017 Q3 2016 IRF Home Health and Hospice Reclasses Consolidated IRF Home Health and Hospice Reclasses Consolidated Net operating revenues $ 794.8 $ 200.8 $ — $ 995.6 $ 751.7 $ 175.1 $ — $ 926.8 Less: Provision for doubtful accounts (11.3) (1.3) — (12.6) (13.7) (1.1) — (14.8) 783.5 199.5 — 983.0 738.0 174.0 — 912.0 Operating Expenses: Inpatient Rehabilitation: Salaries and benefits (403.2) — (138.9) (542.1) (371.2) — (126.2) (497.4) Other operating expenses(a) (117.4) — (17.2) (134.6) (110.1) — (14.6) (124.7) Supplies (33.1) — (3.4) (36.5) (31.9) — (2.9) (34.8) Occupancy (15.7) — (2.9) (18.6) (15.0) — (2.6) (17.6) Home Health and Hospice: Cost of services sold (excluding depreciation and amortization) — (93.5) 93.5 — — (86.8) 86.8 — Support and overhead costs — (68.9) 68.9 — — (59.5) 59.5 — (569.4) (162.4) — (731.8) (528.2) (146.3) — (674.5) Other income 1.0 — — 1.0 0.8 — — 0.8 Equity in net income of nonconsolidated affiliates 1.9 0.2 — 2.1 2.3 0.2 — 2.5 Noncontrolling interest (16.7) (2.5) — (19.2) (14.3) (2.1) — (16.4) Segment Adjusted EBITDA $ 200.3 $ 34.8 $ — 235.1 $ 198.6 $ 25.8 $ — 224.4 General and administrative expenses(b) (30.5) (26.0) Adjusted EBITDA $ 204.6 $ 198.4 In arriving at Adjusted EBITDA, the following were excluded: (a) Loss (gain) on disposal of assets $ 3.1 $ (0.1) $ — $ 3.0 $ 1.6 $ — $ — $ 1.6 (b) Stock-based compensation — — — 9.2 — — — 4.3 Reconciliations to GAAP provided on pages 94-104. Segment Operating Results 

 

Encompass Health 92 Nine Months Ended September 30, 2017 Nine Months Ended September 30, 2016 IRF Home Health and Hospice Reclasses Consolidated IRF Home Health and Hospice Reclasses Consolidated Net operating revenues $ 2,377.3 $ 574.4 $ — $ 2,951.7 $ 2,253.5 $ 503.8 $ — $ 2,757.3 Less: Provision for doubtful accounts (38.4) (4.3) — (42.7) (43.8) (2.9) — (46.7) 2,338.9 570.1 — 2,909.0 2,209.7 500.9 — 2,710.6 Operating Expenses: Inpatient Rehabilitation: Salaries and benefits (1,195.7) — (404.3) (1,600.0) (1,107.2) — (362.4) (1,469.6) Other operating expenses(a) (342.1) — (51.8) (393.9) (321.7) — (43.3) (365.0) Supplies (100.6) — (10.0) (110.6) (96.1) — (8.1) (104.2) Occupancy (46.3) — (8.5) (54.8) (46.0) — (7.5) (53.5) Home Health and Hospice: Cost of services sold (excluding depreciation and amortization) — (271.2) 271.2 — — (246.8) 246.8 — Support and overhead costs — (203.4) 203.4 — — (174.5) 174.5 — (1,684.7) (474.6) — (2,159.3) (1,571.0) (421.3) — (1,992.3) Other income 2.9 — — 2.9 2.1 — — 2.1 Equity in net income of nonconsolidated affiliates 5.6 0.6 — 6.2 6.7 0.6 — 7.3 Noncontrolling interest (48.6) (4.6) — (53.2) (47.9) (5.8) — (53.7) Segment Adjusted EBITDA $ 614.1 $ 91.5 $ — 705.6 $ 599.6 $ 74.4 $ — 674.0 General and administrative expenses(b) (90.7) (79.2) Adjusted EBITDA $ 614.9 $ 594.8 In arriving at Adjusted EBITDA, the following were excluded: (a) Loss (gain) on disposal of assets $ 3.5 $ (0.2) $ — $ 3.3 $ 2.3 $ (0.3) $ — $ 2.0 (b) Stock-based compensation — — — 37.9 — — — 17.4 Reconciliations to GAAP provided on pages 94-104. Segment Operating Results 

 

Encompass Health 93 Segment Operating Results Year Ended December 31, 2016 IRF Home Health and Hospice Reclasses Consolidated Net operating revenues $ 3,021.1 $ 686.1 $ — $ 3,707.2 Less: Provision for doubtful accounts (57.0) (4.2) — (61.2) 2,964.1 681.9 — 3,646.0 Operating Expenses: Inpatient Rehabilitation: Salaries and benefits (1,493.4) — (492.5) (1,985.9) Other operating expenses(a) (431.5) — (59.9) (491.4) Supplies (128.8) — (11.2) (140.0) Occupancy (61.2) — (10.1) (71.3) Home Health and Hospice: Cost of services sold (excluding depreciation and amortization) — (336.5) 336.5 — Support and overhead costs — (237.2) 237.2 — (2,114.9) (573.7) — (2,688.6) Other income 2.9 — — 2.9 Equity in net income of nonconsolidated affiliates 9.1 0.7 — 9.8 Noncontrolling interest (64.0) (6.5) — (70.5) Segment Adjusted EBITDA $ 797.2 $ 102.4 $ — 899.6 General and administrative expenses(b) (106.0) Adjusted EBITDA $ 793.6 In arriving at Adjusted EBITDA, the following were excluded: (a) Loss (gain) on disposal of assets $ 4.3 $ (3.6) $ — $ 0.7 (b) Stock-based compensation expense — — — 27.4 Reconciliations to GAAP provided on pages 94-104. 

 

Encompass Health 94 Reconciliations to GAAP and Share Information 

 

Encompass Health 95 2017 Q1 Q2 Q3 9 Months (in millions, except per share data) Total Per Share Total Per Share Total Per Share Total Per Share Net Income $ 84.4 $ 79.4 $ 85.1 $ 248.9 Loss (income) from disc ops, net of tax, attributable to Encompass Health 0.3 (0.2) 0.1 0.2 Net income attributable to noncontrolling interests (17.6) (16.4) (19.2) (53.2) Income from continuing operations attributable to Encompass Health* 67.1 $ 0.70 62.8 $ 0.66 66.0 $ 0.67 195.9 $ 2.08 Provision for income tax expense 39.7 28.6 43.1 111.4 Interest expense and amortization of debt discounts and fees 41.3 40.4 36.8 118.5 Depreciation and amortization 45.2 45.8 46.2 137.2 Loss on early extinguishment of debt — 10.4 0.3 10.7 Net noncash (gain) loss on disposal of assets (0.5) 0.8 3.0 3.3 Stock-based compensation expense 8.0 20.7 9.2 37.9 Adjusted EBITDA $ 200.8 $ 209.5 $ 204.6 $ 614.9 Weighted average common shares outstanding: Basic 88.8 90.3 97.8 92.3 Diluted 99.0 98.9 99.0 99.1 Reconciliation of Net Income to Adjusted EBITDA(10) * Per share amounts for each period presented are based on diluted weighted-average shares outstanding. Refer to pages 106-109 for end notes. 

 

Encompass Health 96 2016 Q1 Q2 Q3 Q4 Full Year (in millions, except per share data) Total Per Share Total Per Share Total Per Share Total Per Share Total Per Share Net Income $ 76.7 $ 81.2 $ 78.1 $ 82.1 $ 318.1 Loss (income) from disc ops, net of tax, attributable to Encompass Health 0.1 0.1 0.1 (0.3) — Net income attributable to noncontrolling interests (18.7) (18.6) (16.4) (16.8) (70.5) Income from continuing operations attributable to Encompass Health* 58.1 $ 0.61 62.7 $ 0.65 61.8 $ 0.64 65.0 $ 0.68 247.6 $ 2.59 Professional fees — accounting, tax, and legal 0.2 1.7 — — 1.9 Provision for income tax expense 39.7 42.4 42.1 39.7 163.9 Interest expense and amortization of debt discounts and fees 44.6 43.4 42.5 41.6 172.1 Depreciation and amortization 42.4 42.9 43.5 43.8 172.6 Loss on early extinguishment of debt 2.4 2.4 2.6 — 7.4 Net noncash loss (gain) on disposal of assets 0.2 0.2 1.6 (1.3) 0.7 Stock-based compensation expense 4.5 8.6 4.3 10.0 27.4 Adjusted EBITDA $ 192.1 $ 204.3 $ 198.4 $ 198.8 $ 793.6 Weighted average common shares outstanding: Basic 89.5 89.3 89.1 88.6 89.1 Diluted 99.4 99.4 99.4 99.2 99.5 Reconciliation of Net Income to Adjusted EBITDA(10) * Per share amounts for each period presented are based on diluted weighted-average shares outstanding. Refer to pages 106-109 for end notes. 

 

Encompass Health 97 Reconciliation of Segment Adjusted EBITDA to Income from Continuing Operations Before Income Tax Expense Q3 2017 Q2 2017 Q1 2017 Q4 2016 Q3 2016 Q2 2016 Q1 2016 Full Year 2016 (In Millions) Total segment Adjusted EBITDA $ 235.1 $ 241.2 $ 229.3 $ 225.6 $ 224.4 $ 230.1 $ 219.5 $ 899.6 General and administrative expenses (39.7) (52.4) (36.5) (36.8) (30.3) (34.4) (31.9) (133.4) Depreciation and amortization (46.2) (45.8) (45.2) (43.8) (43.5) (42.9) (42.4) (172.6) (Loss) gain on disposal of assets (3.0) (0.8) 0.5 1.3 (1.6) (0.2) (0.2) (0.7) Professional fees — accounting, tax, and legal — — — — — (1.7) (0.2) (1.9) Loss on early extinguishment of debt (0.3) (10.4) — — (2.6) (2.4) (2.4) (7.4) Interest expense and amortization of debt discounts and fees (36.8) (40.4) (41.3) (41.6) (42.5) (43.4) (44.6) (172.1) Net income attributable to noncontrolling interests 19.2 16.4 17.6 16.8 16.4 18.6 18.7 70.5 Income from continuing operations before income tax expense $ 128.3 $ 107.8 $ 124.4 $ 121.5 $ 120.3 $ 123.7 $ 116.5 $ 482.0 

 

Encompass Health 98 For the Three Months Ended September 30, 2017 Adjustments As Reported Mark-to- Market Adjustment for Stock Appreciation Rights Income Tax Adjustments(25) Loss on Early Extinguishment of Debt As Adjusted (In Millions, Except Per Share Amounts) Adjusted EBITDA $ 204.6 $ — $ — $ — $ 204.6 Depreciation and amortization (46.2) — — — (46.2) Loss on early extinguishment of debt(24) (0.3) — — 0.3 — Interest expense and amortization of debt discounts and fees (36.8) — — — (36.8) Stock-based compensation (9.2) (1.0) — — (10.2) Loss on disposal of assets (3.0) — — — (3.0) Income from continuing operations before income tax expense 109.1 (1.0) — 0.3 108.4 Provision for income tax expense (43.1) 0.4 (0.4) (0.1) (43.2) Income from continuing operations attributable to Encompass Health $ 66.0 $ (0.6) $ (0.4) $ 0.2 $ 65.2 Add: Interest, amortization, and loss on extinguishment of convertible debt, net of tax — — Numerator for diluted earnings per share $ 66.0 $ 65.2 Diluted earnings per share from continuing operations, as reported* $ 0.67 $ (0.01) $ — $ — $ 0.66 Diluted shares used in calculation 99.0 Adjusted EPS(11) - Q3 2017 Reconciliation to GAAP provided on pages 94-104. Refer to pages 106-109 for end notes. * Adjusted EPS may not sum across due to rounding. 

 

Encompass Health 99 Adjusted EPS(11) - Q2 2017 For the Three Months Ended June 30, 2017 Adjustments As Reported Mark-to- Market Adjustment for Stock Appreciation Rights Income Tax Adjustments(25) As Adjusted (In Millions, Except Per Share Amounts) Adjusted EBITDA $ 209.5 $ — $ — $ 209.5 Depreciation and amortization (45.8) — — (45.8) Loss on early extinguishment of debt(24) (10.4) — — (10.4) Interest expense and amortization of debt discounts and fees (40.4) — — (40.4) Stock-based compensation (20.7) 11.6 — (9.1) Loss on disposal or impairment of assets (0.8) — — (0.8) Income from continuing operations before income tax expense 91.4 11.6 — 103.0 Provision for income tax expense (28.6) (4.6) (7.4) (40.6) Income from continuing operations attributable to Encompass Health $ 62.8 $ 7.0 $ (7.4) $ 62.4 Add: Interest, amortization, and loss on extinguishment of convertible debt, net of tax 8.3 8.3 Numerator for diluted earnings per share $ 71.1 $ 70.7 Diluted earnings per share from continuing operations $ 0.72 Impact of antidilution $ (0.02) Diluted earnings per share from continuing operations, as reported* $ 0.70 $ 0.07 $ (0.07) $ 0.71 Diluted shares used in calculation 98.9 Reconciliation to GAAP provided on pages 94-104. Refer to pages 106-109 for end notes. * Adjusted EPS may not sum across due to rounding. 

 

Encompass Health 100 Adjusted EPS(11) - Q1 2017 For the Three Months Ended March 31, 2017 Adjustments As Reported Mark-to- Market Adjustment for Stock Appreciation Rights Income Tax Adjustments(25) and Settlements As Adjusted (In Millions, Except Per Share Amounts) Adjusted EBITDA $ 200.8 $ — $ — $ 200.8 Depreciation and amortization (45.2) — — (45.2) Interest expense and amortization of debt discounts and fees (41.3) — — (41.3) Stock-based compensation (8.0) 3.3 — (4.7) Gain on disposal or impairment of assets 0.5 — — 0.5 Income from continuing operations before income tax expense 106.8 3.3 — 110.1 Provision for income tax expense (39.7) (1.3) (2.6) (43.6) Income from continuing operations attributable to Encompass Health $ 67.1 $ 2.0 $ (2.6) $ 66.5 Add: Interest on convertible debt, net of tax 2.5 2.5 Numerator for diluted earnings per share $ 69.6 $ 69.0 Diluted earnings per share from continuing operations* $ 0.70 $ 0.02 $ (0.03) $ 0.70 Diluted shares used in calculation 99.0 Reconciliation to GAAP provided on pages 94-104. Refer to pages 106-109 for end notes. * Adjusted EPS may not sum across due to rounding. 

 

Encompass Health 101 For the Nine Months Ended September 30, 2017 Adjustments As Reported Mark-to- Market Adjustment for Stock Appreciation Rights Loss on Early Extinguishment of Debt Income Tax Adjustments(25) As Adjusted (In Millions, Except Per Share Amounts) Adjusted EBITDA $ 614.9 $ — $ — $ — $ 614.9 Depreciation and amortization (137.2) — — — (137.2) Loss on early extinguishment of debt(24) (10.7) — 0.3 — (10.4) Interest expense and amortization of debt discounts and fees (118.5) — — — (118.5) Stock-based compensation (37.9) 13.9 — — (24.0) Loss on disposal of assets (3.3) — — — (3.3) Income from continuing operations before income tax expense 307.3 13.9 0.3 — 321.5 Provision for income tax expense (111.4) (5.6) (0.1) (10.4) (127.5) Income from continuing operations attributable to Encompass Health $ 195.9 $ 8.3 $ 0.2 $ (10.4) $ 194.0 Add: Interest, amortization, and loss on extinguishment of convertible debt, net of tax 10.8 10.8 Numerator for diluted earnings per share $ 206.7 $ 204.8 Diluted earnings per share from continuing operations, as reported* $ 2.08 $ 0.08 $ — $ (0.10) $ 2.07 Diluted shares used in calculation 99.1 Adjusted EPS(11) - YTD 2017 Reconciliation to GAAP provided on pages 94-104. Refer to pages 106-109 for end notes. * Adjusted EPS may not sum across due to rounding. 

 

Encompass Health 102 For the Year Ended December 31, 2016 Adjustments As Reported Pro. Fees - Acct., Tax, & Legal Mark-to- Market Adjustment for Stock Appreciation Rights Loss on Early Exting. of Debt Sale of Pediatric Home Health Assets and Hospital Income Tax Valuation and Other Adjustments As Adjusted (In Millions, Except Per Share Amounts) Adjusted EBITDA $ 793.6 $ — $ — $ — $ — $ — $ 793.6 Depreciation and amortization (172.6) — — — — — (172.6) Professional fees — accounting, tax, and legal (1.9) 1.9 — — — — — Loss on early extinguishment of debt (7.4) — — 7.4 — — — Interest expense and amortization of debt discounts and fees (172.1) — — — — — (172.1) Stock-based compensation (27.4) — 1.6 — — — (25.8) Loss on disposal of assets (0.7) — — — (4.2) — (4.9) Income from continuing operations before income tax expense 411.5 1.9 1.6 7.4 (4.2) — 418.2 Provision for income tax expense (163.9) (0.8) (0.6) (3.0) 6.5 (0.6) (162.4) Income from continuing operations attributable to Encompass Health $ 247.6 $ 1.1 $ 1.0 $ 4.4 $ 2.3 $ (0.6) $ 255.8 Add: Interest on convertible debt, net of tax 9.7 9.7 Numerator for diluted earnings per share $ 257.3 $ 265.5 Diluted earnings per share from continuing operations* $ 2.59 $ 0.01 $ 0.01 $ 0.04 $ 0.02 $ (0.01) $ 2.67 Diluted shares used in calculation 99.5 Adjusted EPS(11) - 2016 Reconciliation to GAAP provided on pages 94-104. Refer to pages 106-109 for end notes. * Adjusted EPS may not sum across due to rounding. 

 

Encompass Health 103 Adjusted Free Cash Flow History(12) Q3 9 Months Full Year (Millions) 2017 2016 2017 2016 2016 Net cash provided by operating activities $ 173.8 $ 177.6 $ 505.8 $ 499.4 $ 634.4 Impact of discontinued operations 0.1 0.1 0.7 0.6 0.7 Net cash provided by operating activities of continuing operations 173.9 177.7 506.5 500.0 635.1 Capital expenditures for maintenance (37.6) (23.9) (92.1) (64.5) (104.2) Distributions paid to noncontrolling interests of consolidated affiliates (14.2) (15.9) (38.3) (49.5) (64.9) Items non-indicative of ongoing operating performance: Transaction costs and related assumed liabilities — — — 0.8 0.8 Net premium on bond issuance/repayment — 1.9 — 5.8 5.8 Cash paid for professional fees — accounting, tax, and legal — — — 1.9 1.9 Adjusted free cash flow $ 122.1 $ 139.8 $ 376.1 $ 394.5 $ 474.5 Cash dividends on common stock(13) $ 23.5 $ 20.5 $ 67.0 $ 62.4 $ 83.8 Refer to pages 106-109 for end notes. Information regarding investing and financing categories of the statement of cash flows for the periods presented can be found on Encompass Health’s website in the Earnings Releases for those periods. 

 

Encompass Health 104 Net Cash Provided by Operating Activities Reconciled to Adjusted EBITDA Information regarding investing and financing categories of the statement of cash flows for the periods presented can be found on Encompass Health’s website in the Earnings Releases for those periods. Q3 9 Months Full Year (Millions) 2017 2016 2017 2016 2016 2015 2014 2013 2012 Net cash provided by operating activities $ 173.8 $ 177.6 $ 505.8 $ 499.4 $ 634.4 $ 502.0 $ 454.6 $ 476.1 $ 423.4 Provision for doubtful accounts (12.6) (14.8) (42.7) (46.7) (61.2) (47.2) (31.6) (26.0) (27.0) Professional fees — accounting, tax, and legal — — — 1.9 1.9 3.0 9.3 9.5 16.1 Interest expense and amortization of debt discounts and fees 36.8 42.5 118.5 130.5 172.1 142.9 109.2 100.4 94.1 Equity in net income of nonconsolidated affiliates 2.1 2.5 6.2 7.3 9.8 8.7 10.7 11.2 12.7 Net income attributable to noncontrolling interests in continuing operations (19.2) (16.4) (53.2) (53.7) (70.5) (69.7) (59.7) (57.8) (50.9) Amortization of debt-related items (1.0) (3.5) (7.7) (10.3) (13.8) (14.3) (12.7) (5.0) (3.7) Distributions from nonconsolidated affiliates (2.2) (2.9) (6.6) (5.9) (8.5) (7.7) (12.6) (11.4) (11.0) Current portion of income tax expense 36.0 4.6 60.1 13.6 31.0 14.8 13.3 6.3 5.9 Change in assets and liabilities (9.8) 6.4 32.6 51.7 91.3 129.9 80.4 43.1 46.2 Net premium paid on bond transactions — 1.9 — 5.8 5.8 3.9 4.3 1.7 1.9 Cash used in (provided by) operating activities of discontinued operations 0.1 0.1 0.7 0.6 0.7 0.7 1.2 1.9 (2.0) Transaction costs — — — — — 12.3 9.3 — — Other 0.6 0.4 1.2 0.6 0.6 3.2 1.9 1.6 0.2 Adjusted EBITDA $ 204.6 $ 198.4 $ 614.9 $ 594.8 $ 793.6 $ 682.5 $ 577.6 $ 551.6 $ 505.9 

 

Encompass Health 105 Share Information Refer to pages 106-109 for end notes. Weighted Average for the Period Q3 9 Months Full Year 2017 2016 2017 2016 2016 Basic shares outstanding(26) 97.8 89.1 92.3 89.3 89.1 Convertible senior subordinated notes(26) — 8.5 5.4 8.5 8.5 Restricted stock awards, dilutive stock options, restricted stock units, and common stock warrants(27) 1.2 1.8 1.4 1.7 1.9 Diluted shares outstanding 99.0 99.4 99.1 99.5 99.5 End of Period Q3 9 Months Full Year (Millions) 2017 2016 2017 2016 2016 Basic shares outstanding(26) 97.6 89.1 97.6 89.1 88.3 

 

Encompass Health 106 End Notes 

 

Encompass Health 107 (1) Under this program, Joint Commission accredited organizations, like the Company’s IRFs, may seek certification for chronic diseases or conditions such as brain injury or stroke rehabilitation by complying with Joint Commission standards, effectively using evidence-based clinical practice guidelines to manage and optimize patient care, and using an organized approach to performance measurement and evaluation of clinical outcomes. Obtaining such certifications demonstrates the Company’s commitment to excellence in providing disease-specific care. (2) Data compares Encompass Health IRFs to IRFs comprising the Uniform Data System for Medical Rehabilitation (“UDSMR”), a division of UB Foundation Activities, Inc., a data gathering and analysis organization for the rehabilitation industry which represents approximately 70% of the industry, including Encompass Health sites. Data is adjusted by applying Encompass Health IRF case-mix to non-Encompass Health UDS IRFs. (3) Source: https://data.medicare.gov/data/home-health-compare. Data on this page was published in October 2017 and reflects OASIS and HHCAHPS Survey data collected from April 2016 through March 2017 and claims-based data collected from January 2016 through December 2016. (4) The 123 for Encompass Health excludes the inpatient rehabilitation hospitals at HealthSouth Rehabilitation Hospital of Modesto (opened October 2016); HealthSouth Rehabilitation Hospital of Gulfport (opened April 2017); Mount Carmel Rehabilitation Hospital, in partnership with HealthSouth (opened April 2017); Spire Rehabilitation Hospital, in partnership with HealthSouth (opened July 2017); and HealthSouth Rehabilitation Hospital of Beaumont (sold June 2016). The 123 does include HealthSouth Rehabilitation Hospital of Austin, which was closed August 2016. (5) In 2016, the Company averaged 1,386 total Medicare and non-Medicare discharges per IRF in its then 118 consolidated IRFs that were open the full year. (6) Case Mix Index (CMI) from the rate-setting file is adjusted for short-stay transfer cases. The Company’s unadjusted CMI for 2016 was 1.36 versus 1.33 for the industry as measured by UDSMR. (7) Source: FY 2018 CMS Final Rule Rate Setting File and the last publicly available Medicare cost reports (FYE 2015/2016) or in the case of new IRFs, the June 2017 CMS Provider of Service File. a.All data provided was filtered and compiled from the Centers for Medicare and Medicaid Services (CMS) Fiscal Year 2018 IRF Final Rule Rate Setting File found at https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/InpatientRehabFacPPS/Downloads/FY2018_datafiles_final.zip. The data presented was developed entirely by CMS and is based on its definitions which are different in form and substance from the criteria Encompass Health uses for external reporting purposes. Because CMS does not provide its detailed methodology, Encompass Health is not able to reconstruct the CMS projections or the calculation. b.The CMS file contains data for each of the 1,140 inpatient rehabilitation facilities used to estimate the policy updates for the FY 2018 IRF-PPS Final Rule. Most of the data represents historical information from the CMS fiscal year 2016 period and may or may not reflect the same Encompass Health IRFs in operation today. The data presented was separated into three categories: Freestanding, Units, and Encompass Health. Encompass Health is a subset of Freestanding and the Total. (8) The Budget Control Act of 2011 included a reduction of up to 2% to Medicare payments for all providers that began on April 1, 2013 (as modified by H.R. 8). The reduction was made from whatever level of payment would otherwise have been provided under Medicare law and regulation. (9) The Company acquired an additional 30% equity interest in Fairlawn Rehabilitation Hospital in Worcester, MA from its joint venture partner. This transaction increased the Company’s ownership interest from 50% to 80% and resulted in a change in accounting for the hospital from the equity method to a consolidated entity effective June 1, 2014. (10) Adjusted EBITDA is a non-GAAP financial measure. The Company’s leverage ratio (total consolidated debt to Adjusted EBITDA for the trailing four quarters) is, likewise, a non-GAAP measure. Management and some members of the investment community utilize Adjusted EBITDA as a financial measure and the leverage ratio as a liquidity measure on an ongoing basis. These measures are not recognized in accordance with GAAP and should not be viewed as an alternative to GAAP measures of performance or liquidity. In evaluating Adjusted EBITDA, the reader should be aware that in the future the Company may incur expenses similar to the adjustments set forth. Further explanation and disclosure relating to Adjusted EBITDA are included in the Company’s Form 8-K, dated January 8, 2018, to which this Investor Reference Book is attached as Exhibit 99.2. End Notes 

 

Encompass Health 108 (11) The Company is providing adjusted earnings per share from continuing operations attributable to Encompass Health (“adjusted earnings per share”), which is a non-GAAP measure. The Company believes the presentation of adjusted earnings per share provides useful additional information to investors because it provides better comparability of ongoing operating performance to prior periods given that it excludes the impact of government, class action, and related settlements, professional fees - accounting, tax, and legal, mark-to-market adjustments for stock appreciation rights, gains or losses related to hedging instruments, loss on early extinguishment of debt, adjustments to its income tax provision (such as valuation allowance adjustments and settlements of income tax claims), items related to corporate and facility restructurings, and certain other items deemed to be non- indicative of ongoing operating performance. It is reasonable to expect that one or more of these excluded items will occur in future periods, but the amounts recognized can vary significantly from period to period and may not directly relate to the Company’s ongoing operating performance. Accordingly, they can complicate comparisons of the Company’s results of operations across periods and comparisons of the Company’s results to those of other healthcare companies. Adjusted earnings per share should not be considered as a measure of financial performance under generally accepted accounting principles in the United States as the items excluded from it are significant components in understanding and assessing financial performance. Because adjusted earnings per share is not a measurement determined in accordance with GAAP and is thus susceptible to varying calculations, it may not be comparable as presented to other similarly titled measures of other companies. Further explanation and disclosure relating to adjusted EPS are included in the Company’s Form 8-K, dated January 8, 2018, to which this Investor Reference Book is attached as Exhibit 99.2. (12) Definition of adjusted free cash flow, which is a non-GAAP measure, is net cash provided by operating activities of continuing operations minus capital expenditures for maintenance, dividends paid on preferred stock, distributions to noncontrolling interests, and certain other items deemed to be non- indicative of ongoing operating performance. Common stock dividends are not included in the calculation of adjusted free cash flow. Because this measure is not determined in accordance with GAAP and is susceptible to varying calculations, it may not be comparable to other similarly titled measures presented by other companies. Further explanation and disclosure relating to adjusted free cash flow are included in the Company’s Form 8-K, dated January 8, 2018, to which this Investor Reference Book is attached as Exhibit 99.2. Note: Adjusted free cash flow for prior periods has been recast to conform to the new guidance in ASU 2016-09, “Improvements to Employee Share- Based Payment Accounting.” The Company’s stock-based compensation plans permit shares to be withheld to pay the employee’s tax withholding obligations incurred in connection with the vesting of a stock award. The Company then remits the value of those withheld shares in cash to the applicable tax authority on the employee’s behalf. Under the new guidance, all cash payments made to taxing authorities on employees’ behalf for shares withheld should be presented as a financing activity in the statement of cash flows. Historically, the Company presented such payments as an operating activity. Adjusted Free Cash Flow As Previously Reported Payroll Taxes Paid Reclassified to Financing Activities As Currently Reported Q1 2016 $ 129.5 $ 9.9 $ 139.4 Q2 2016 115.3 — 115.3 Q3 2016 139.8 — 139.8 Q4 2016 78.3 1.7 80.0 FY 2016 $ 462.9 $ 11.6 $ 474.5 (13) On July 21, 2016, the board of directors approved a $0.01 per share, or 4.3%, increase to the quarterly cash dividend on the Company’s common stock, bringing the quarterly cash dividend to $0.24 per common share. On July 20, 2017, the board of directors approved a $0.01 per share, or 4.2%, increase to the quarterly cash dividend on the Company’s common stock, bringing the quarterly cash dividend to $0.25 per common share. (14) The Medicare Access and CHIP Reauthorization Act of 2015 mandated a market basket update of +1.0% in 2018 for post-acute providers including inpatient rehabilitation hospitals as well as home health and hospice agencies. End Notes, con't. 

 

Encompass Health 109 (15) The Company estimates the expected impact of each rule utilizing, among other things, the acuity of its patients over the 8-month (home health segment) to 12-month (inpatient rehabilitation segment) period prior to each rule’s release and incorporates other adjustments included in each rule. These estimates are prior to the impact of sequestration. (16) Quality reporting requirements and potential penalties were enabled for IRFs as part of the Healthcare Reform Bill (PPACA). The IMPACT Act of 2014 requires additional quality and clinical data reporting for IRFs to be subject to the original 2% penalty. (17) Pre-opening expenses include expenses for training new employees on the clinical information system, which vary based on the timing of the first admission. (18) The leverage ratio is based on trailing four quarters of Adjusted EBITDA of $813.7 million from Q4 2016 to Q3 2017. (19) Represents discharges from 125 consolidated IRFs in Q3 2017; 124 consolidated IRFs in Q2 2017; 122 consolidated IRFs in Q1 2017 and Q4 2016; 121 consolidated IRFs in Q3 2016; 120 consolidated IRFs in Q2 2016; and 121 consolidated IRFs in Q1 2016. (20) Excludes approximately 440 full-time equivalents in the 2017 periods and approximately 420 full-time equivalents in the 2016 periods presented who are considered part of corporate overhead with their salaries and benefits included in general and administrative expenses in the Company’s consolidated statements of operations. Full-time equivalents included in the table represent Encompass Health employees who participate in or support the operations of the Company’s IRFs. (21) Employees per occupied bed, or “EPOB,” is calculated by dividing the number of full-time equivalents, including an estimate of full-time equivalents from the utilization of contract labor, by the number of occupied beds during each period. The number of occupied beds is determined by multiplying the number of licensed beds by the Company’s occupancy percentage. (22) Represents home health admissions from 196 consolidated locations in Q3 2017; 191 consolidated locations in Q2 2017 and Q1 2017; 186 consolidated locations in Q4 2016; 188 consolidated locations in Q3 2016; 187 consolidated locations in Q2 2016; and 184 consolidated locations in Q1 2016 (23) Represents hospice admissions from 37 locations in Q3 2017 and Q2 2017; 35 locations in Q1 2017 and Q4 2016; 33 locations in Q3 2016; 29 locations in Q2 2016; and 27 locations in Q1 2016 (24) The income allocated to participating securities need to be subtracted from income from continuing operations to calculate basic earnings per share.The interest and amortization and the loss on early extinguishment of debt related to the convertible senior subordinated notes must be added to income from continuing operations when calculating diluted earnings per share because the debt was assumed to have been converted at the beginning of the period, and the applicable shares were included in the diluted share count. (25) New guidance in ASU 2016-09, “Improvements to Employee Share-Based Payment Accounting,” requires entities to record all of the tax effects related to share-based payments at settlement (or expiration) through the income statement. Historically, the Company recorded such tax effects to equity. (26) In November 2013, the Company closed separate, privately negotiated exchanges in which it issued $320 million of 2.0% Convertible Senior Subordinated Notes due 2043 in exchange for 257,110 shares of its 6.5% Series A Convertible Perpetual Preferred Stock. The Company recorded ~$249 million as debt and ~$71 million as equity. In May 2017, the Company provided notice of its intent to redeem all $320 million of outstanding convertible notes. In lieu of receiving the redemption price, the holders had the right to convert their notes into shares of the Company’s common stock at a conversion rate of 27.2221 shares per $1,000 principal amount of Notes, which rate was increased by a make-whole premium. In the aggregate, holders of $319.4 million in principal elected to convert, which resulted in the Company issuing 8,895,483 shares of common stock (approximately 8.6 million shares were previously included in the diluted share count). The remaining $0.6 million of principal was redeemed by cash payment. (27) The agreement to settle the Company’s class action securities litigation received final court approval in January 2007. The 5.0 million shares of common stock and warrants to purchase ~8.2 million shares of common stock at a strike price of $41.40 (expired January 17, 2017) related to this settlement were issued on September 30, 2009. The 5.0 million common shares are included in the basic outstanding shares. The warrants were not included in the diluted share count prior to 2015 because the strike price had historically been above the market price. In full-year 2016 and full-year 2014, zero shares related to the warrants were included in the diluted share count due to antidilution based on the stock price. In full-year 2015, 80,814 shares related to the warrants were included in the diluted share count using the treasury stock method. End Notes, con't.